<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis - Virgili, G - 2023 | Cochrane Library</title> <meta content="Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis - Virgili, G - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub7/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis - Virgili, G - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub7/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007419.pub7" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis" name="citation_title"/> <meta content="Gianni Virgili&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Florence" name="citation_author_institution"/> <meta content="gianni.virgili@unifi.it" name="citation_author_email"/> <meta content="Katie Curran&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Ersilia Lucenteforte" name="citation_author"/> <meta content="University of Pisa" name="citation_author_institution"/> <meta content="Tunde Peto" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Mariacristina Parravano" name="citation_author"/> <meta content="Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD007419.pub7" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub7/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub7/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007419.pub7/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bevacizumab [therapeutic use]; *Diabetes Mellitus [drug therapy]; *Diabetic Retinopathy [complications, drug therapy]; Endothelial Growth Factors [therapeutic use]; Laser Coagulation [methods]; *Macular Edema [drug therapy, etiology, surgery]; Network Meta-Analysis; Ranibizumab [therapeutic use]; Vascular Endothelial Growth Factor A" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007419.pub7&amp;doi=10.1002/14651858.CD007419.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007419\x2epub7\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007419\x2epub7\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ko","th","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007419.pub7",title:"Anti\\u2010vascular endothelial growth factor for diabetic macular oedema: a network meta\\u2010analysis",firstPublishedDate:"Jun 27, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub7&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007419.pub7';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007419.pub7/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007419.pub7/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub7%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007419.PUB7" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007419.pub7/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007419.PUB7" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007419.pub7/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007419.pub7/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3110 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007419.pub7" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-sec-0079"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-sec-0073"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/appendices#CD007419-sec-0084"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/supinfo/CD007419-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/supinfo/CD007419-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#CD007419-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Gianni Virgili</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#CD007419-cr-0005">Katie Curran</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#CD007419-cr-0006">Ersilia Lucenteforte</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#CD007419-cr-0007">Tunde Peto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information#CD007419-cr-0008">Mariacristina Parravano</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information/en#CD007419-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007419.pub7">https://doi.org/10.1002/14651858.CD007419.pub7</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007419-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007419-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007419-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007419-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007419-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007419-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD007419-abs-0007">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007419-abs-0001" lang="en"> <section id="CD007419-sec-0001"> <h3 class="title" id="CD007419-sec-0001">Background</h3> <p>Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor (anti‐VEGF) can reduce oedema, improve vision, and prevent further visual loss. These drugs have replaced laser photocoagulation as the standard of care for people with DMO. In the previous update of this review, we found moderate‐quality evidence that, at 12 months, aflibercept was slightly more effective than ranibizumab and bevacizumab for improving vision in people with DMO, although the difference may have been clinically insignificant (less than 0.1 logarithm of the minimum angle of resolution (logMAR), or five Early Treatment Diabetic Retinopathy Study (ETDRS) letters, or one ETDRS line). </p> </section> <section id="CD007419-sec-0002"> <h3 class="title" id="CD007419-sec-0002">Objectives</h3> <p>The objective of this updated review was to compare the effectiveness and safety of the different anti‐VEGF drugs in RCTs at longer follow‐up (24 months). </p> </section> <section id="CD007419-sec-0003"> <h3 class="title" id="CD007419-sec-0003">Search methods</h3> <p>We searched various electronic databases on 8 July 2022.</p> </section> <section id="CD007419-sec-0004"> <h3 class="title" id="CD007419-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared any anti‐angiogenic drug with an anti‐VEGF mechanism of action versus another anti‐VEGF drug, another treatment, sham, or no treatment in people with DMO. </p> </section> <section id="CD007419-sec-0005"> <h3 class="title" id="CD007419-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods for pairwise meta‐analysis and we augmented this evidence using network meta‐analysis (NMA) methods. We used the Stata 'network' meta‐analysis package for all analyses. We used the CINeMA (Confidence in Network Meta‐Analysis) web application to grade the certainty of the evidence. </p> </section> <section id="CD007419-sec-0006"> <h3 class="title" id="CD007419-sec-0006">Main results</h3> <p>We included 23 studies (13 with industry funding) that enrolled 3513 people with DMO (median central retinal thickness (CRT) 460 microns, interquartile range (IQR) 424 to 482) and moderate vision loss (median best‐corrected visual acuity (BCVA) 0.48 logMAR, IQR 0.42 to 0.55). One study that investigated ranibizumab versus sham and one study that mainly enrolled people with subclinical DMO and normal BCVA were not suitable for inclusion in the efficacy NMA. </p> <p>Consistent with the previous update of this review, we used ranibizumab as the reference drug for efficacy, and control (including laser, observation, and sham) as the reference for systemic safety. </p> <p>Eight trials provided data on the primary outcome (change in BCVA at 24 months, in logMAR: lower is better). We found no evidence of a difference between the following interventions and ranibizumab alone: aflibercept (mean difference (MD) −0.05 logMAR, 95% confidence interval (CI) −0.12 to 0.02; moderate certainty); bevacizumab (MD ‐0.01 logMAR, 95% CI −0.13 to 0.10; low certainty), brolucizumab (MD 0.00 logMAR, 95% CI −0.08 to 0.07; low certainty), ranibizumab plus deferred laser (MD 0.00 logMAR, 95% CI −0.11 to 0.10; low certainty), and ranibizumab plus prompt laser (MD 0.03 logMAR, 95% CI −0.04 to 0.09; very low certainty).  </p> <p>We also analysed BCVA change at 12 months, finding moderate‐certainty evidence of increased efficacy with brolucizumab (MD −0.07 logMAR, 95%CI −0.10 to −0.03 logMAR), faricimab (MD −0.08 logMAR, 95% CI −0.12 to −0.05), and aflibercept (MD −0.07 logMAR, 95 % CI −0.10 to −0.04) compared to ranibizumab alone, but the difference could be clinically insignificant.  </p> <p>Compared to ranibizumab alone, NMA of six trials showed no evidence of a difference with aflibercept (moderate certainty), bevacizumab (low certainty), or ranibizumab with prompt (very low certainty) or deferred laser (low certainty) regarding improvement by three or more ETDRS lines at 24 months. </p> <p>There was moderate‐certainty evidence of greater CRT reduction at 24 months with brolucizumab (MD −23 microns, 95% CI −65 to −1 9) and aflibercept (MD −26 microns, 95% CI −53 to 0.9) compared to ranibizumab. There was moderate‐certainty evidence of lesser CRT reduction with bevacizumab (MD 28 microns, 95% CI 0 to 56), ranibizumab plus deferred laser (MD 63 microns, 95% CI 18 to 109), and ranibizumab plus prompt laser (MD 72 microns, 95% CI 25 to 119) compared with ranibizumab alone. </p> <p>Regarding all‐cause mortality at the longest available follow‐up (20 trials), we found no evidence of increased risk of death for any drug compared to control, although effects were in the direction of an increase, and clinically relevant increases could not be ruled out. The certainty of this evidence was low for bevacizumab (risk ratio (RR) 2.10, 95% CI 0.75 to 5.88), brolucizumab (RR 2.92, 95% CI 0.68 to 12.58), faricimab (RR 1.91, 95% CI 0.45 to 8.00), ranibizumab (RR 1.26, 95% CI 0.68 to 2.34), and very low for conbercept (RR 0.33, 95% CI 0.01 to 8.81) and aflibercept (RR 1.48, 95% CI 0.79 to 2.77). Estimates for Antiplatelet Trialists Collaboration arterial thromboembolic events at 24 months did not suggest an increase with any drug compared to control, but the NMA was overall incoherent and the evidence was of low or very low certainty. </p> <p>Ocular adverse events were rare and poorly reported and could not be assessed in NMAs.</p> </section> <section id="CD007419-sec-0007"> <h3 class="title" id="CD007419-sec-0007">Authors' conclusions</h3> <p>There is limited evidence of the comparative efficacy and safety of anti‐VEGF drugs beyond one year of follow‐up. We found no clinically important differences in visual outcomes at 24 months in people with DMO, although there were differences in CRT change. We found no evidence that any drug increases all‐cause mortality compared to control, but estimates were very imprecise. Evidence from RCTs may not apply to real‐world practice, where people in need of antiangiogenic treatment are often under‐treated, and the individuals exposed to these drugs may be less healthy than trial participants. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007419-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007419-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007419-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007419-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007419-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007419-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007419-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007419-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD007419-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007419-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007419-abs-0002" lang="en"> <h3>Anti‐vascular endothelial growth factor (anti‐VEGF) medicines for diabetic macular oedema </h3> <p><b>What is the aim of this review?</b><br/>The aim of this Cochrane Review was to find out which is the best type of anti‐vascular endothelial growth factor (anti‐VEGF) medicine for diabetic macular oedema (DMO) two years after treatment initiation. </p> <p><b>Key messages</b><br/>There may be no clinically important differences in visual outcomes among anti‐VEGF medicines at two years in people with DMO, although we did find differences in the effect of medicines on retinal thickness. There is no evidence that any medicine increases the risk of death or major cardiovascular events compared to control. </p> <p><b>What is diabetic macular oedema?</b><br/>The light‐sensitive tissue at the back of the eye is known as the retina. The central area of the retina is called the macula. People with diabetes can develop problems in the retina, known as retinopathy. Some people with diabetic retinopathy can also develop oedema (swelling or thickening) at the macula. DMO is a common complication of diabetic retinopathy and can lead to visual loss. </p> <p><b>How is diabetic macular oedema treated?</b><br/>One type of treatment for DMO is anti‐VEGF. This type of medicine is given by means of an injection into the eye. It can reduce the swelling at the back of the eye and prevent visual loss. These medicines might have unwanted effects, particularly related to the blood vessels in the rest of the body. </p> <p><b>What did we want to find out?</b><br/>The previous version of this review found minor differences in effects between anti‐VEGF medicines at one year, which were unlikely to be clinically significant. In this update, we investigated if any differences in efficacy and safety exist after two years. </p> <p><b>What did we do?</b><br/>We included all studies comparing anti‐VEGF medicines with each other or with control and summarised data at two years. </p> <p><b>What did we find?</b><br/>We found 23 relevant studies. Thirteen were industry‐sponsored studies from the USA, Europe, or Asia. Ten studies received no industry funding and were from the USA, Europe, the Middle East, and South America. </p> <p>There were results at two years for the medicines ranibizumab, bevacizumab, aflibercept, and brolucizumab. One study investigated conbercept, but this medicine is approved only in China. Results were available only at one year for the newest medicine faricimab. These anti‐VEGF medicines were compared with no treatment, sham treatment, laser treatment, or each other. People participating in the studies received the medicines every month for the first three to six months, then less frequently. Decisions about long‐term treatment were based on visual acuity or by looking at the back of the eye. </p> <p>We found that all anti‐VEGF medicines prevent visual loss and can improve vision in people with DMO, with no important differences in vision at two years between aflibercept, bevacizumab, brolucizumab, and ranibizumab, although aflibercept and brolucizumab yield a better control of retinal swelling than other medicines. </p> <p>There was no evidence that these medicines increase the risk of death or cardiovascular events, but the quality of this evidence was poor. </p> <p><b>What are the limitations of the evidence?</b><br/>Few studies provided data comparing anti‐VEGF medicines at two years, and estimates were often imprecise. </p> <p><b>How up to date is this review?</b><br/>We searched for studies that had been published up to 6 October 2021. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007419-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007419-sec-0079"></div> <h3 class="title" id="CD007419-sec-0080">Implications for practice</h3> <section id="CD007419-sec-0080"> <p>In people with centre‐involved diabetic macular oedema (DMO), aflibercept, bevacizumab, brolucizumab, and ranibizumab improved vision at 24 months. The differences among drugs are unlikely to be clinically significant, but the certainty of the evidence is variable, and the number of studies is small. Aflibercept and brolucizumab may reduce retinal thickening more than other drugs, with uncertain clinical significance. Only 12‐month data were available for faricimab, which, together with aflibercept, may be more effective than ranibizumab and bevacizumab for improving vision at this shorter follow‐up. </p> <p>We found no differences in safety measures between antiangiogenic drugs that are currently available to treat DMO; however, our estimates were imprecise, inconsistent, or both imprecise and inconsistent for Antiplatelet Trialists Collaboration arterial thromboembolic events and all‐cause mortality. </p> </section> <h3 class="title" id="CD007419-sec-0081">Implications for research</h3> <section id="CD007419-sec-0081"> <p>The evidence used to build the NMA was much sparser at 24 months compared to 12 months, because most trials became open‐label after one year. There is a need to generate more evidence on the long‐term (two years or longer) comparative effects of these anti‐vascular endothelial growth factor (anti‐VEGF) agents, including the switch between different drugs. Observational studies based on large electronic databases or registries should investigate systemic and ocular safety, particularly in people with diabetes or high cardiovascular risk. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007419-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007419-sec-0008"></div> <div class="table" id="CD007419-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: mean change in best‐corrected visual acuity from baseline to 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, brolucizumab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcome:</b> mean change in BCVA at 24 months, measured in logMAR (lower is better) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> 0.1 logMAR (equivalent to 5 ETDRS letters, or 1 ETDRS line) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>g</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (641)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05logMAR</b> (−0.12 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.5</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (261)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.01 logMAR</b> (−0.13 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.00logMAR</b> (−0.08 to 0.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.00logMAR</b> (−0.11 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (287)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03logMAR</b> (−0.04 to 0.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (598)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.13 logMAR</b> (0.6 to 0.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>ETDRS</b> : Early Treatment Diabetic Retinopathy Study; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>MD:</b> mean difference; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Relative to mean BCVA change from baseline with ranibizumab alone (−0.19 logMAR in 3 trials, 341 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (0.1 logMAR) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded for incoherence: direct and indirect evidence 95% prediction intervals differ, and their interpretation supports different conclusions favouring one treatment (−1 level) or either treatment (−2 levels).<br/><sup>d</sup> Downgraded (−2 levels) for publication bias, since two‐year data were only available for one of two substudies (KESTREL) on ClinicalTrials.gov and as an ARVO abstract.<br/><sup>e</sup> Downgraded for heterogeneity: 95% predictive interval, but not meta‐analytic estimate, exceeding the clinical significance threshold (0.1 logMAR) on one side (−1 level) or both sides (−2 levels).<br/><sup>f</sup> Downgraded for within‐study risk of bias.<br/><sup>g</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 53.3. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007419-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: mean change in best‐corrected visual acuity from baseline to 12 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, conbercept, faricimab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone (11 studies, 1140 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcome:</b> mean change in BCVA at 12 months (lower is better) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> 0.1 logMAR (equivalent to 5 ETDRS letters, or 1 ETDRS line) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>e</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Faricimab (PTI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.08logMAR</b> (−0.12 to −0.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (1592)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.07logMAR</b> (−0.10 to −0.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1(368)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.07logMAR</b> (−0.10 to −0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conbercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05logMAR</b> (−0.11 to 0.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (373)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.01 logMAR</b> (−0.04 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01logMAR</b> (−0.04 to 0.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (746)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01logMAR</b> (−0.01 to 0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (1296)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.12logMAR</b> (0.10 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>ETDRS</b> : Early Treatment Diabetic Retinopathy Study; <b>logMAR:</b> logarithm of the minimum angle of resolution<i>;</i><b>MD:</b> mean difference; <b>PTI:</b> personalised treatment interval; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Relative to mean BCVA change from baseline with ranibizumab (−0.20 logMAR in 11 studies, 1140 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (0.1 logMAR) on one side (−1 level).<br/><sup>c</sup> Downgraded for within‐study risk of bias (‐1 level).<br/><sup>d</sup> Downgraded for incoherence: direct and indirect evidence 95% prediction intervals differ, and their interpretation supports different conclusions favouring one treatment (−1 level).<br/><sup>e</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 34.8. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007419-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: gain of three or more ETDRS lines from baseline to 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, brolucizumab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone (2 studies, 224 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcome:</b> gain of 3 or more ETDRS lines from baseline to 24 months </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> RR 0.80 to 1.25 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute risk (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative risk (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>d</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (487)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.30 to 0.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.10</b> (0.87 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (185)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.25 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.97</b> (0.74 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.17 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.80</b> (0.49 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.16 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.76</b> (0.46 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (559)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.11 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.47</b> (0.32 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>ETDRS</b> : Early Treatment Diabetic Retinopathy Study; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve<sup>c</sup>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Relative risk with intervention multiplied by absolute risk with ranibizumab alone (0.34 in 2 trials, 224 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (RR 0.80 or 1.25) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded for within‐study risk of bias (‐1 level).<br/><sup>d</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 69.4. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007419-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: mean change in central retinal thickness from baseline to 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, brolucizumab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone (1 study, 191 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcome:</b> mean change in CRT at 24 months (microns, lower is better) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> 50 microns </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>c</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (640)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−26 microns</b> (−53 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−23microns</b> (−65 to −19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (261)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28 microns</b> (0 to 56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63microns</b> (18 to 109) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72microns</b> (25 to 119) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (563)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75microns</b> (42 to 109) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CRT:</b> central retinal thickness; <b>MD:</b> mean difference; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Relative to median CRT change from baseline with ranibizumab (−135 microns in 1 trial, 191 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (50 microns) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 68.9. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007419-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: all‐cause mortality at longest available follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs (aflibercept, bevacizumab, brolucizumab, conbercept, faricimab, ranibizumab) </p> <p><b>Comparison:</b> control (15 studies, 2126 participants), including laser, observation, sham </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcome:</b> all‐cause mortality at longest available follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> RR 0.80 to 1.25 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug (vs. control)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. studies</b> </p> <p><b>(no. participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute risk<sup>a</sup> (95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>e</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2644)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.027 (0.014 to 0.050)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.48</b> (0.79 to 2.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (305)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.038 (0.014 to 0.106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.10</b> (0.75 to 5.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (368)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.053 (0.012 to 0.227)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.92</b> (0.68 to 12.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conbercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.006 (0.0 to 0.159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.33</b> (0.01 to 8.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Faricimab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1262)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.034 (0.008 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.91</b> (0.45 to 8.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (2065)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.023 (0.012 to 0.042)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.26</b> (0.68 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.4</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Relative risk for drug vs. control multiplied by absolute risk with control (0.018 in 15 trials, 2126 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (RR= 0.80 or 1.25) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded for incoherence: direct and indirect evidence 95% prediction intervals differ, and their interpretation supports different conclusions favouring one treatment (−1 level) or either treatment (−2 levels).<br/><sup>d</sup> Downgraded for within‐study risk of bias (‐1 level).<br/><sup>e</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The control value was 75.8 (higher number means safer). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007419-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings: Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs (aflibercept, bevacizumab, brolucizumab, conbercept, faricimab, ranibizumab) </p> <p><b>Comparison:</b> control (13 studies, 1619 participants), including laser, observation, sham (risk = 0.044) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcome:</b> Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> RR 0.80 to 1.25 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute risk (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative risk (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRAf</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2701)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.048 (0.028 to 0.081)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.08</b> (0.63 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (310)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.043 (0.017 to 0.106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.97</b> (0.39 to 2.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (369)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.021 (0.007 to 0.068)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.48</b> (0.15 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conbercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.044 (0.009 to 0.194)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.99</b> (0.20 to 4.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Faricimab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1262)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.040 (0.014 to 0.114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.91</b> (0.32 to 2.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (1501)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.047 (0.027 to 0.081)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.06</b> (0.63 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Relative risk for drug vs. control multiplied by absolute risk for control (0.044 in 13 trials, 1619 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (RR &lt; 0.80 or &gt; 1.25) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded one level for incoherence: direct and indirect evidence points to opposite direction and has poor overlap.<br/><sup>d</sup> Only indirect evidence: not downgraded further as large imprecision already means uncertain effect, including clinically significant increase.<br/><sup>e</sup> Downgraded for within‐study bias (‐1 level).<br/><sup>f</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The control value was 46.1. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007419-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007419-sec-0009"></div> <section id="CD007419-sec-0010"> <h3 class="title" id="CD007419-sec-0010">Description of the condition</h3> <p>Diabetic retinopathy (DR) is the most frequent and severe ocular complication of diabetes mellitus (DM) and the leading cause of blindness in the working age population in high‐income countries (<a href="./references#CD007419-bbs2-0101" title="FrankRN . Diabetic retinopathy. New England Journal of Medicine2004;350(1):48-58.">Frank 2004</a>; <a href="./references#CD007419-bbs2-0114" title="KleinR , KleinBE , MossSE , DavisMD , DeMetsDL . The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology1984;91(12):1464-74.">Klein 1984</a>; <a href="./references#CD007419-bbs2-0143" title="TranosPG , WickremasingheSS , StangosNT , TopouzisF , TsinopoulosI , PavesioCE . Macular edema. Survey of Ophthalmology2004;49(5):470-90.">Tranos 2004</a>). </p> <p>Diabetic macular oedema (DMO) is the swelling of the retina resulting from the exudation and accumulation of extracellular fluid and proteins in the macula (<a href="./references#CD007419-bbs2-0087" title="CiullaTA , AmadorAG , ZinmanB . Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care2003;26(9):2653-64.">Ciulla 2003</a>), due to the breakdown of the blood‐retina barrier with an increase in vascular permeability (<a href="./references#CD007419-bbs2-0074" title="AntcliffRJ , MarshallJ . The pathogenesis of edema in diabetic maculopathy. Seminars in Ophthalmology1999;14(4):223-32.">Antcliff 1999</a>). Around one‐third of people with diabetes have DR and one in 10 is affected by DMO (<a href="./references#CD007419-bbs2-0146" title="YauJW , RogersSL , KawasakiR , LamoureuxEL , KowalskiJW , BekT , et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012;35(3):556-64.">Yau 2012</a>). The prevalence of DMO increases with diabetes duration, haemoglobin A1c, and blood pressure levels, and is higher in people with type 1 compared with type 2 diabetes (<a href="./references#CD007419-bbs2-0146" title="YauJW , RogersSL , KawasakiR , LamoureuxEL , KowalskiJW , BekT , et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012;35(3):556-64.">Yau 2012</a>). </p> <p>Intraretinal fluid accumulation results in significant reduction in visual acuity that may be reversible in the short term, but prolonged oedema can cause irreversible damage resulting in permanent visual loss. Blurred vision represents the most common clinical symptom of DMO. Other symptoms include metamorphopsia (distortion of visual image), floaters, changes in contrast sensitivity, photophobia (visual intolerance to light), changes in colour vision, and scotomas (a localised defect of the visual field). </p> <p>Since the 1980s, the clinical gold standard to detect macular oedema has been fundus examination with contact lens, but non‐contact lenses can also be used for this purpose with good sensitivity. Optical coherence tomography (OCT) is increasingly used as an objective and reproducible tool to measure retinal thickness, and some experts suggest it could constitute the new gold standard for diagnosing DMO (<a href="./references#CD007419-bbs2-0123" title="OlsonJ , SharpP , GoatmanK , PrescottG , ScotlandG , FlemingA , et al. Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study. Health Technology Assessment2013;17(51):1-142.">Olson 2013</a>; <a href="./references#CD007419-bbs2-0124" title="Medical Advisory Secretariat. Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis. Ontario Health Technology Assessment Series2009;9(13):1-22.">Ontario HTA 2009</a>). The most severe form of DMO is clinically significant macular oedema (CSMO), which the Early Treatment Diabetic Retinopathy Study (ETDRS) defines as a condition that meets any of the following criteria (<a href="./references#CD007419-bbs2-0096" title="Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Archives of Ophthalmology1985;103(12):1796-806.">ETDRS 1985</a>). </p> <p> <ul id="CD007419-list-0001"> <li> <p>Retinal oedema within 500 µm of the centre of the fovea</p> </li> <li> <p>Hard exudates within 500 µm of the centre of the fovea, if associated with adjacent retinal thickening (which may be outside the 500 µm limit) </p> </li> <li> <p>One disc area of retinal oedema (1500 µm) or larger, any part of which is within one disc diameter of the centre of the fovea </p> </li> </ul> </p> <p>Since the introduction of OCT, research has demonstrated good agreement between this technique and the clinical gold standard (slit‐lamp examination with a contact lens) for detecting the presence of macular oedema; moreover, OCT may be more sensitive in cases of mild foveal thickening (<a href="./references#CD007419-bbs2-0081" title="BrownJC , SolomonSD , BresslerSB , SchachatAP , DiBernardoC , BresslerNM . Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Archives of Ophthalmology2004;122(3):330-5.">Brown 2004</a>). A simple OCT‐based classification defines DMO as centre‐involving or non‐centre‐involving (<a href="./references#CD007419-bbs2-0082" title="BrowningDJ , AltaweelMM , BresslerNM , BresslerSB , ScottIU , Diabetic Retinopathy Clinical Research Network. Diabetic macular edema: what is focal and what is diffuse?American Journal of Ophthalmology2008;146(5):649-55.">Browning 2008</a>). </p> </section> <section id="CD007419-sec-0011"> <h3 class="title" id="CD007419-sec-0011">Description of the intervention</h3> <p>Antiangiogenic therapy has largely replaced laser photocoagulation and become a standard of care for the treatment of DMO (<a href="./references#CD007419-bbs2-0111" title="JampolLM , BresslerNM , GlassmanAR . Revolution to a new standard treatment of diabetic macular edema. JAMA2014;311(22):2269-70.">Jampol 2014</a>, <a href="./references#CD007419-bbs2-0154" title="VirgiliG , ParravanoM , MenchiniF , EvansJR . Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub4]">Virgili 2014</a>). The UK National Institute for Clinical Excellence (NICE) technology appraisal guidance recommends anti‐vascular endothelial growth factor (VEGF) agents only for people with DMO of at least 400 microns, as anti‐VEGFs are not cost‐effective below this threshold<a href="https://www.nice.org.uk/guidance/ta346" target="_blank">https://www.nice.org.uk/guidance/ta346</a>(<a href="./references#CD007419-bbs2-0140" title="National Institute for Clinical Excellence (NICE) - Technology appraisal guidance. Ranibizumab for treating diabetic macular oedema. www.nice.org.uk/guidance/ta274 (accessed 23 January 2023).">TA274 2013</a>; <a href="./references#CD007419-bbs2-0141" title="National Institute for Clinical Excellence (NICE) - Technology appraisal guidance. Aflibercept for treating diabetic macular oedema. www.nice.org.uk/guidance/ta346 (accessed 23 January 2023).">TA346 2015</a>; <a href="./references#CD007419-bbs2-0142" title="National Institute for Clinical Excellence (NICE) - Technology appraisal guidance. Faricimab for treating diabetic macular oedema. www.nice.org.uk/guidance/ta799 (accessed 23 January 2023).">TA799 2022</a>). The previous version of this review found minor differences between anti‐VEGF drugs at one year; these differences were likely to be clinically unimportant (<a href="./references#CD007419-bbs2-0155" title="VirgiliG , ParravanoM , EvansJR , GordanI , LucenteforteE , Cochrane Eyes and Vision Group. Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 10 CD007419. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub6]">Virgili 2018</a>). Anti‐VEGF treatments inhibit VEGF angiogenic activity, binding to VEGF protein and thus preventing its receptor activation or interaction. Researchers originally hypothesised that these drugs could be an alternative adjunctive treatment for DMO (<a href="./references#CD007419-bbs2-0089" title="Cunningham ET Jr, AdamisAP , AltaweelM , AielloLP , BresslerNM , D'AmicoDJ , et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology2005;112(10):1747-57.">Cunningham 2005</a>), following evidence that VEGF‐A plays a key role in the occurrence of increased vascular permeability in ocular diseases such as DMO (<a href="./references#CD007419-bbs2-0073" title="AielloLP . Angiogenic pathways in diabetic retinopathy. New England Journal of Medicine2005;353(8):839-41.">Aiello 2005</a>). </p> <p>Grid or focal laser photocoagulation is not suitable for all people with DMO; therefore, initial studies on the efficacy of antiangiogenic drugs for DMO used either laser or sham procedures as current practice comparators (<a href="./references#CD007419-bbs2-0052" title="Cunningham ET Jr, AdamisAP , AltaweelM , AielloLP , BresslerNM , D'AmicoDJ , et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology2005;112(10):1747-57. ">Macugen 2005</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>), and no directly comparative randomised controlled trials (RCTs) were published until 2015 (<a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>). One 2022 study showed subthreshold macular laser to be as effective as standard laser in people with centre‐involved DMO and retinal thickness below 400 microns (<a href="./references#CD007419-bbs2-0118" title="LoisN , CampbellC , WaughN , Azuara-BlancoA , MaredzaM , MistryH , et al, DIAMONDS study group. DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser (DIAMONDS): A randomized double-masked non-inferiority clinical trial. Ophthalmology2023;130(1):14-27.">Lois 2022</a>), for whom anti‐VEGF is generally not recommended (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>). </p> <p>Intravitreal antiangiogenic therapy has acceptable safety; endophthalmitis, the major adverse event (fewer than 1/1000 injections) is related to the surgical injection procedure, rather than the drug itself. </p> <p>Steroids represent another therapeutic option for DMO. They are administered as intravitreal injections or sustained release implants to obtain high local concentrations, maximising their anti‐inflammatory, angiostatic, and anti‐permeability effects while minimising systemic toxicity (<a href="./references#CD007419-bbs2-0088" title="CiullaTA , WalkerJD , FongDS , CriswellMH . Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Current Opinions in Ophthalmology2004;15(3):211-20.">Ciulla 2004</a>; <a href="./references#CD007419-bbs2-0106" title="HallerJA , KuppermannBD , BlumenkranzMS , WilliamsGA , WeinbergDV , ChouC , et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Archives of Ophthalmology2010;128(3):289-96.">Haller 2010</a>; <a href="./references#CD007419-bbs2-0116" title="KuppermannBD , ChouC , WeinbergDV , WhitcupSM , HallerJA , BlumenkranzMS . Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Archives of Ophthalmology2010;128(5):642-3.">Kuppermann 2010</a>). However, intravitreal steroids may cause cataract and ocular hypertension, and the visual outcome is dependent on the lens status or the need for cataract surgery after about one year (<a href="./references#CD007419-bbs2-0083" title="CampochiaroPA , HeierJS , FeinerL , GrayS , SarojN , RundleAC , et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology2010;117(6):1102-12.">Campochiaro 2010</a>; <a href="./references#CD007419-bbs2-0106" title="HallerJA , KuppermannBD , BlumenkranzMS , WilliamsGA , WeinbergDV , ChouC , et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Archives of Ophthalmology2010;128(3):289-96.">Haller 2010</a>). Some investigators consider that intravitreal steroids are preferable in people with anti‐VEGF‐resistant and chronic DMO, as an alternative to switching between anti‐VEGF drugs (<a href="./references#CD007419-bbs2-0110" title="HussainRM , CiullaTA . Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opinion on Biological Therapy2016;16(3):365-74.">Hussain 2015</a>). This is consistent with the EU label of the only approved dexamethasone intravitreal implant in Europe: "Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non‐corticosteroid therapy" (<a href="./references#CD007419-bbs2-0092" title="European Medicines Agency. Ozurdex Product Information. Available at www.ema.europa.eu/en/medicines/human/EPAR/ozurdex (accessed 9 March 2023).">EMA 2022a</a>). </p> <p>For ranibizumab, the EU label prescribes a 0.5 mg dosage, and indicates that "treatment is initiated with one injection per month until maximum visual acuity is achieved and/or there are no signs of disease activity i.e. no change in visual acuity and in other signs and symptoms of the disease under continued treatment. In patients with wet AMD [age‐related macular degeneration], DME, PDR [proliferative diabetic retinopathy] and RVO [retinal vein occlusion], initially, three or more consecutive, monthly injections may be needed. Thereafter, monitoring and treatment intervals should be determined by the physician and should be based on disease activity, as assessed by visual acuity and/or anatomical parameters" (<a href="./references#CD007419-bbs2-0093" title="European Medicines Agency. Lucentis Product Information. Available at www.ema.europa.eu/en/medicines/human/EPAR/lucentis (accessed 9 March 2023).">EMA 2022b</a>). In the USA, ranibizumab "0.3 mg is recommended to be administered by intravitreal injection once a month (approximately 28 days)" (<a href="./references#CD007419-bbs2-0098" title="US Food and Drug Administration. LUCENTIS (ranibizumab injection) label. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf (accessed 9 March 2023).">FDA 2014</a>). </p> <p>Aflibercept is approved for use in the USA, and "the recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months)" (<a href="./references#CD007419-bbs2-0097" title="US Food and Drug Administration. EYLEA (afilbercept) injection label. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf (accessed 9 March 2023).">FDA 2011</a>). The EU label is similar (<a href="./references#CD007419-bbs2-0094" title="European Medicines Agency. Eylea Product Information. Available at www.ema.europa.eu/en/medicines/human/EPAR/eylea (accessed 9 March 2023).">EMA 2023a</a>). </p> <p>Bevacizumab is widely used off‐label; its use has been questioned based on regulatory and safety issues (<a href="./references#CD007419-bbs2-0076" title="BanfiR , AttanasioF , PalazziN , ColombiniS , FalaiT , CecchiM , et al. Bevacizumab versus ranibizumab: why are we not playing the joker?International Journal of Clinical Pharmacy2013;35(4):507-9.">Banfi 2013</a>), but is still key for treating chorioretinal vascular disease in low‐ and middle‐income countries thanks to its low cost (<a href="./references#CD007419-bbs2-0138" title="StewartMW , NarayananR , GuptaV , RosenfeldPJ , MartinDF , ChakravarthyU . Counterfeit Avastin in India: punish the criminals, not the patients. American Journal of Ophthalmology2016;170:228-31.">Stewart 2016</a>). </p> <p>More recently, anti‐VEGF drugs with longer duration of effects have been made available with the goal of extending treatment intervals and reducing the number of injections. These include brolucizumab (<a href="./references#CD007419-bbs2-0095" title="European Medicines Agency. Beovu European public assessment report. Available at www.ema.europa.eu/en/medicines/human/EPAR/beovu (accessed 9 March 2023).">EMA 2023b</a>; <a href="./references#CD007419-bbs2-0099" title="US Food and Drug Administration. Drug Approval Package: BEOVU (brolucizumab-dbll). Available at www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761125_Orig1_toc.cfm (accessed 9 March 2023).">FDA 2019</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>) and faricimab (<a href="./references#CD007419-bbs2-0100" title="US Food and Drug Administration. VABYSMO Highlights of prescribing information. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf (accessed 9 March 2023).">FDA 2022</a>: <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). </p> <p>Conbercept is another anti‐VEGF drug for intravitreal use; it has been approved to treat AMD and DMO in China only (<a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>). </p> </section> <section id="CD007419-sec-0012"> <h3 class="title" id="CD007419-sec-0012">How the intervention might work</h3> <p>VEGF plays a key role in the occurrence of increased vascular permeability in ocular diseases such as DMO (<a href="./references#CD007419-bbs2-0073" title="AielloLP . Angiogenic pathways in diabetic retinopathy. New England Journal of Medicine2005;353(8):839-41.">Aiello 2005</a>). Anti‐VEGF agents inhibit VEGF angiogenic activity, binding to VEGF protein and thus preventing its receptor activation and interaction, with various degree of affinity (<a href="./references#CD007419-bbs2-0127" title="ParravanoM , CostanzoE , ScondottoG , TrifiròG , VirgiliG . Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update. BioDrugs2021;35(6):673-92.">Parravano 2021</a>). The targets differ between drugs, and newer drugs also bind other cytokines, such as angiopoietin 2 (Ang‐2) inhibitor (<a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). </p> </section> <section id="CD007419-sec-0013"> <h3 class="title" id="CD007419-sec-0013">Why it is important to do this review</h3> <p>DMO results in a significant burden of low vision and blindness, hence the importance of assessing and updating the evidence base for the effectiveness and safety of these agents. There is a continuing clinical need to establish evidence‐based recommendations regarding anti‐VEGF agents. The previous version of this review provided estimates of the relative safety and efficacy of different antiangiogenic drugs to treat DMO at 12 months. There is evidence that about two‐thirds of people with DMO need treatment up to five years, although the number of injections may be low after year 2, and only 8% of participants received 20 or more injections in years 3 to 5 (<a href="./references#CD007419-bbs2-0103" title="GlassmanAR , Wells JA 3rd, JosicK , MaguireMG , AntoszykAN , BakerC , et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology2020;1272:12001-10.">Glassman 2020</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007419-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007419-sec-0014"></div> <p>The objective of this updated review was to compare the effectiveness and safety of the different anti‐VEGF drugs in RCTs at longer follow‐up (24 months). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007419-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007419-sec-0015"></div> <section id="CD007419-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007419-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs.</p> </section> <section id="CD007419-sec-0018"> <h4 class="title">Types of participants</h4> <p>People with DMO and an indication for anti‐VEGF treatment (in most settings this means OCT evidence of central retinal thickness (CRT) above 400 microns). We expected to include most of the studies included in <a href="./references#CD007419-bbs2-0155" title="VirgiliG , ParravanoM , EvansJR , GordanI , LucenteforteE , Cochrane Eyes and Vision Group. Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 10 CD007419. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub6]">Virgili 2018</a>, except those with follow‐up shorter than nine months. </p> </section> <section id="CD007419-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies that evaluated any antiangiogenic drug with anti‐VEGF modalities versus another antiangiogenic drug with anti‐VEGF modalities, laser treatment, sham, or no treatment. The <a href="#CD007419-sec-0011">Description of the intervention</a> section presents the reasons for selecting both direct and indirect treatments. As explained in <a href="#CD007419-sec-0011">Description of the intervention</a>, steroids may be comparable to anti‐VEGF drugs, but they require a different approach, specifically regarding patient subgroups and timing. Consequently, including studies that evaluate steroids could lead to violation of similarity in a review aiming to compare different anti‐VEGF drugs, and so we decided to exclude steroids. </p> <p>Regarding drug dose and monitoring/retreatment regimen, in efficacy analyses we included schemes that were either on‐label or commonly used in clinical practice, such as the treatment as needed (PRN) regimen, as presented in the <a href="#CD007419-sec-0011">Description of the intervention</a> section. For ranibizumab, both 0.3 mg and 0.5 mg doses were eligible. We merged these two ranibizumab doses into one group in our network meta‐analysis (NMA), as studies have found no difference between them when used monthly (<a href="./references#CD007419-bbs2-0107" title="HeierJS , BresslerNM , AveryRL , BakriSJ , BoyerDS , BrownDM , et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmology2016;134(1):95-9.">Heier 2016</a>). Regarding aflibercept, we selected the eight‐weekly retreatment regimen, as this is the approved label in the first year. We used all available data regardless of dose and regimen for safety analyses, in accordance with <a href="./references#CD007419-bbs2-0120" title="MojaL , LucenteforteE , KwagKH , BerteleV , CampomoriA , ChakravarthyU , et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD011230. [DOI: 10.1002/14651858.CD011230.pub2]">Moja 2014</a> and the previous version of this review. </p> </section> <section id="CD007419-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007419-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>We considered that mean continuous best‐corrected visual acuity (BCVA) was the preferred outcome measure in trials on DMO at the time of this update. We also recognised a need for longer‐term results, as people with DMO are followed for several years and tend to stabilise during the second year of treatment. </p> <p>Therefore, the primary outcome for this update was change in BCVA (logarithm of the minimum angle of resolution (logMAR: lower is better)), measured using ETDRS charts, between baseline and 24 months. </p> </section> <section id="CD007419-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007419-list-0002"> <li> <p>Mean change in BCVA from baseline to 12 months, measured using ETDRS charts</p> </li> <li> <p>Proportion of participants with at least 15 ETDRS letters (three ETDRS lines or 0.3 logMAR) of improvement in BCVA from baseline to 24 months </p> </li> <li> <p>Mean change in CRT from baseline to 24 months, measured using OCT</p> </li> <li> <p>Mean change in quality of life from baseline to 24 months, measured using a validated instrument </p> </li> <li> <p>Need for rescue laser within 24 months' follow‐up</p> </li> </ul> </p> <p>We pooled measurements at varying lengths of follow‐up in annual intervals, plus or minus six months, the primary analysis being that at 24 months. Where multiple time points were available, we chose the time point closest to 24 months, or the latest time point in the window frame in the case of symmetry. </p> </section> <section id="CD007419-sec-0023"> <h5 class="title">Adverse events</h5> <p>Most large studies reported a large number of adverse events, often grouped by ocular anatomic district, or, if systemic, by MedDRA (Medical Dictionary for Regulatory Activities) system organ class. Based on our experience with the previous version of this review, we decided to report adverse events for which we believe further evidence should be collected (<a href="./references#CD007419-bbs2-0113" title="KhananiAM , ZarbinMA , BarakatMR , AlbiniTA , KaiserPK , BG , et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmology2022;140(1):20-8.">Khanani 2022</a>; <a href="./references#CD007419-bbs2-0131" title="ReibaldiM , FallicoM , AvitabileT , MaroloP , ParisiG , CennamoG , et al. Frequency of intravitreal anti-VEGF injections and risk of death: a systematic review with meta-analysis. Ophthalmology. Retina2022;6:369-76.">Reibaldi 2022</a>). </p> <p>We considered the following adverse events.</p> <p> <ul id="CD007419-list-0003"> <li> <p>All‐cause mortality</p> </li> <li> <p>Antiplatelet Trialists Collaboration (ATC) arterial thromboembolic events (<a href="./references#CD007419-bbs2-0075" title="Anonymous. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ1994;308(6921):81-106.">ATC 1994</a>) </p> </li> <li> <p>Ocular serious adverse events, as defined by the investigators, and including at least endophthalmitis, severe retinal vascular occlusion, and retinal detachment. We planned to present the frequency of each event in tabular form. </p> </li> </ul> </p> <p>We analysed adverse events at the longest available follow‐up time (<a href="./references#CD007419-bbs2-0120" title="MojaL , LucenteforteE , KwagKH , BerteleV , CampomoriA , ChakravarthyU , et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD011230. [DOI: 10.1002/14651858.CD011230.pub2]">Moja 2014</a>), as in the previous version of this review (<a href="./references#CD007419-bbs2-0155" title="VirgiliG , ParravanoM , EvansJR , GordanI , LucenteforteE , Cochrane Eyes and Vision Group. Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 10 CD007419. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub6]">Virgili 2018</a>). </p> </section> </section> </section> <section id="CD007419-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007419-sec-0025"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases and registries for RCTs and controlled clinical trials, applying no language or publication year restrictions. The date of the search was 8 July 2022. </p> <p> <ul id="CD007419-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, which contains the Cochrane Eyes and Vision Trials Register; 2021, Issue 10) in the Cochrane Library (searched 8 July 2022; <a href="./appendices#CD007419-sec-0085">Appendix 1</a>) </p> </li> <li> <p>MEDLINE Ovid (1946 to 8 July 2022; <a href="./appendices#CD007419-sec-0086">Appendix 2</a>) </p> </li> <li> <p>Embase Ovid (1980 to 8 July 2022; <a href="./appendices#CD007419-sec-0087">Appendix 3</a>) </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database; 1982 to 8 July 2022; <a href="./appendices#CD007419-sec-0088">Appendix 4</a>) </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 6 October 2021; <a href="./appendices#CD007419-sec-0089">Appendix 5</a>) </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 8 July 2022; <a href="./appendices#CD007419-sec-0090">Appendix 6</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="https://trialsearch.who.int" target="_blank">trialsearch.who.int</a>; searched 8 July 2022; <a href="./appendices#CD007419-sec-0091">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD007419-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of the included trials for other possible trials. We accessed the Novartis Clinical Trials database (<a href="https://www.novartis.com/clinicaltrials" target="_blank">www.novartis.com/clinicaltrials</a>) on 28 May 2014 and checked all trials indexed under the headings "ophthalmic disorders" and "ranibizumab". </p> </section> </section> <section id="CD007419-sec-0027"> <h3 class="title" id="CD007419-sec-0027">Data collection and analysis</h3> <section id="CD007419-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently selected the studies for inclusion (KC, MP, IG). First, we examined the titles and abstracts of all reports identified by the electronic searches and handsearching, classifying them as definitely eligible, potentially eligible, and definitely ineligible. We obtained and assessed full‐text copies of all eligible and potential records, and classified studies as included, awaiting assessment, and excluded. The review authors were unmasked to the study authors, institutions, and trial results during this assessment. We resolved any disagreements by involving a third review author (GV). </p> </section> <section id="CD007419-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted the data for the primary and secondary outcomes into Excel forms developed by Cochrane Eyes and Vision (KC, MP). We piloted this form on a few studies. We resolved any discrepancies by discussion. One review author entered all data into Review Manager Web (<a href="./references#CD007419-bbs2-0132" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>), and a second review author checked the entered data. If standard deviations (SDs) were not reported in the publication and could not be obtained from the study authors, we imputed them from SDs of other studies with the same comparison. </p> </section> <section id="CD007419-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KC, MP) independently assessed the included trials for risk of bias according to the methods described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007419-bbs2-0109" title="HigginsJP , AltmanDG , SterneJAC , (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.">Higgins 2017</a>). We assessed the following parameters. </p> <p> <ul id="CD007419-list-0005"> <li> <p>Random sequence generation and allocation concealment</p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ul> </p> <p>We judged each study at low, high, or unclear risk of bias, for each parameter.</p> <p>If the information available in the published trial reports was inadequate to assess methodological quality, we contacted the trial authors for clarification. In our protocol, we specified that if the trial authors did not respond within six months, we would assess the trial based on the available information (<a href="./references#CD007419-bbs2-0151" title="ParravanoM , MenchiniF . Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Systematic Reviews2008, Issue 4. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419]">Parravano 2008</a>). However, for this update of the review, we waited only one month. </p> </section> <section id="CD007419-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>Data analysis followed the guidelines set out in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007419-bbs2-0090" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). For dichotomous outcomes, we calculated a summary risk ratio (RR) with its 95% confidence interval (CI). For continuous outcomes, we calculated the mean difference (MD) and 95% CI. If studies had used different scales to measure the same continuous outcome, we would have calculated standardised mean differences (SMDs). </p> <p>We did not use ranking measures in this review, as we were mainly interested in only three drugs: aflibercept, bevacizumab, and ranibizumab. </p> </section> <section id="CD007419-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the eye of individual participants. We included one cross‐over study comparing ranibizumab and bevacizumab, and we treated it as a parallel study (<a href="./references#CD007419-bbs2-0068" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology.2015;122(10):2044-52. WileyHE , ThompsonDJ , BaileyC , ChewEY , CukrasCA , JaffeGJ , et al. A crossover design for comparative efficacy: a 36-week randomized trial of bevacizumab and ranibizumab for diabetic macular edema. Ophthalmology2016;123(4):841-9. ">Wiley 2016</a>), assuming a moderate (0.5) within‐participant correlation. However, relative drug safety is impossible to assess with a paired design. </p> <p>We accepted studies presenting systemic adverse events as the unit of analyses (i.e. when an individual experienced more than one severe adverse event in the study). </p> </section> <section id="CD007419-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>Where data were missing due to dropouts, we conducted a primary analysis based on participants with complete data (available case analysis). Following the guidance available in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007419-bbs2-0108" title="HigginsJP , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), we considered that missing outcome data were missing at random if the reasons for loss to follow‐up were documented and judged to be unrelated to outcome in both study arms. </p> </section> <section id="CD007419-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>In standard pairwise meta‐analyses, we estimated heterogeneity variances for each direct comparison. We assessed the presence of statistical heterogeneity within each pairwise comparison using the I² statistic (<a href="./references#CD007419-bbs2-0109" title="HigginsJP , AltmanDG , SterneJAC , (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.">Higgins 2017</a>). The assessment of statistical heterogeneity in the entire network was based on the magnitude of the heterogeneity variance parameter (Tau²) estimated from the NMA models. </p> </section> <section id="CD007419-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>To investigate small‐study bias at the network level, we employed the comparison‐adjusted funnel plot, which is an adaptation of the funnel plot. We subtracted from each study‐specific effect size the mean of meta‐analysis of the study‐specific comparison and plotted it against the study's standard error (<a href="./references#CD007419-bbs2-0085" title="ChaimaniA , HigginsJP , MavridisD , SpyridonosP , SalantiG . Graphical tools for network meta-analysis in STATA. PLoS One2013;8(10):e76654.">Chaimani 2013</a>). </p> </section> <section id="CD007419-sec-0036"> <h4 class="title">Data synthesis</h4> <section id="CD007419-sec-0037"> <h5 class="title">Methods for direct treatment comparisons</h5> <p>If there was no substantial statistical heterogeneity and no clinical heterogeneity between trials, we combined the results in a meta‐analysis using a random‐effects model. We used a fixed‐effect model if the number of trials was three or less. In the case of substantial statistical heterogeneity (i.e. I² value above 50%) or clinical heterogeneity, we combined the results in a meta‐analysis using a random‐effects model if the individual trial results had a consistent direction of effect (i.e. RR or MD and CIs largely fell on one side of the null line); when the individual trial results had an inconsistent direction of effect, we did not combine study results but presented a narrative or tabulated summary of each study. </p> </section> <section id="CD007419-sec-0038"> <h5 class="title">Methods for indirect and mixed comparisons</h5> <p>We performed NMA using the multivariate meta‐analysis model, considering different treatment comparisons as different outcomes (<a href="./references#CD007419-bbs2-0133" title="SalantiG . Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods2012;3(2):80-97.">Salanti 2012</a>). For this analysis, we used the 'network' suite of commands available in Stata (<a href="./references#CD007419-bbs2-0137" title="Stata. Version 17. College Station, TX, USA: StataCorp, 2021.">Stata 2021</a>; <a href="./references#CD007419-bbs2-0145" title="WhiteIR . Network meta-analysis. Stata Journal2015;15:951-85.">White 2015</a>). </p> <p>We presented mixed effects as RRs for dichotomous outcomes and MDs for continuous outcomes, each with their 95% CIs. We prepared league tables presenting mixed comparisons in the lower left corner and direct comparisons in the upper right corner, to enable inspection of both types of evidence. </p> </section> <section id="CD007419-sec-0039"> <h5 class="title">Assessment of statistical inconsistency</h5> <section id="CD007419-sec-0040"> <h6 class="title">Local approaches for evaluating inconsistency</h6> <p>To evaluate the presence of inconsistency locally, we used the node‐splitting approach (<a href="./references#CD007419-bbs2-0091" title="DiasS , WeltonNJ , CaldwellDM , AdesAE . Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine2010;29:932-944.">Dias 2010</a>). We assumed a common heterogeneity estimate within each loop. </p> </section> <section id="CD007419-sec-0041"> <h6 class="title">Global approaches for evaluating inconsistency</h6> <p>To check the assumption of consistency in the entire network, we used the 'design‐by‐treatment' model through the 'network' command in Stata (<a href="./references#CD007419-bbs2-0137" title="Stata. Version 17. College Station, TX, USA: StataCorp, 2021.">Stata 2021</a>; <a href="./references#CD007419-bbs2-0145" title="WhiteIR . Network meta-analysis. Stata Journal2015;15:951-85.">White 2015</a>). This method accounts for different sources of inconsistency that can occur when studies with different designs (two‐arm trials versus three‐arm trials) give different results, as well as any disagreement between direct and indirect evidence. Using this approach, we judged the presence of inconsistency from any source in the entire network based on a Chi² test. </p> </section> </section> </section> <section id="CD007419-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We identified too few studies to conduct subgroup analyses of efficacy at 24 months.</p> <p>In most studies with 24‐month data, participants had baseline BCVA between 0.35 and 0.8 logMAR and CRT between 400 and 500 microns, except for <a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a> (excluded) and <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a> (CRT below 300 microns). </p> </section> <section id="CD007419-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>In the previous update of this review, we conducted post‐hoc sensitivity analyses excluding studies at high risk of bias, which did not change our conclusions (<a href="./references#CD007419-bbs2-0155" title="VirgiliG , ParravanoM , EvansJR , GordanI , LucenteforteE , Cochrane Eyes and Vision Group. Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 10 CD007419. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub6]">Virgili 2018</a>). In this update, there were too few trials with data at 24 months to conduct such analyses. </p> </section> <section id="CD007419-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared one summary of findings table for each of the following outcomes.</p> <p> <ul id="CD007419-list-0006"> <li> <p>Mean BCVA change from baseline to 24 months</p> </li> <li> <p>Mean BCVA change from baseline to 12 months</p> </li> <li> <p>Gain of three or more ETDRS lines from baseline to 24 months</p> </li> <li> <p>Mean change in CRT from baseline to 24 months</p> </li> <li> <p>All‐cause death at longest available follow‐up</p> </li> <li> <p>ATC arterial thrombotic events at longest available follow‐up</p> </li> </ul> </p> <p>Because most of the available evidence is still on ranibizumab, we reported on the comparison of each intervention versus ranibizumab alone for efficacy outcomes. We used control (including laser, observation, and sham) as a comparator for safety outcomes. </p> <p>We graded the certainty of the evidence for mixed estimates using the CINeMA platform (<a href="./references#CD007419-bbs2-0122" title="NikolakopoulouA , HigginsJP , PapakonstantinouT , ChaimaniA , Del GiovaneC , EggerM , et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Medicine2020;17:e1003082.">Nikolakopoulou 2020</a>). We estimated the absolute risk in the control group from the data in the included studies as the raw proportion with event for dichotomous outcomes and the median value for continuous outcomes. We took into account the recommendations provided in Chapters 11 and 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007419-bbs2-0086" title="ChaimaniA , CaldwellDM , LiT , HigginsJPT , SalantiG . Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Chaimani 2022</a>; <a href="./references#CD007419-bbs2-0135" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , GuyattGH . Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Schunemann 2022</a>)<i>,</i> as well as guidance provided by <a href="./references#CD007419-bbs2-0147" title="Yepes-NuñezJJ , LiSA , GuyattG , JackSM , BrozekJL , BeyeneJ , et al. Development of the summary of findings table for network meta-analysis. Journal of Clinical Epidemiology2019;115:1-13.">Yepes‐Nuñez 2019</a>. The CINeMA platform and methodological framework evaluates the confidence in the results from NMAs in the following six domains. </p> <p> <ul id="CD007419-list-0007"> <li> <p>Within‐study bias (referring to the impact of risk of bias in the included studies)</p> </li> <li> <p>Reporting bias (referring to publication and other reporting bias)</p> </li> <li> <p>Indirectness</p> </li> <li> <p>Imprecision</p> </li> <li> <p>Heterogeneity</p> </li> <li> <p>Incoherence</p> </li> </ul> </p> <p>In the CINeMA framework, heterogeneity and incoherence are two dimensions of inconsistency that describe the extent to which the prediction interval overlaps with the CI, and the significance testing of the difference between direct and indirect evidence when both are available for a comparison. </p> <p>Decisions regarding imprecision, heterogeneity and incoherence require the specification of a range of equivalence for relative effects (RR) based on absolute effects. For mean change in visual acuity, we considered one ETDRS line (0.1 logMAR) to be the minimal clinically important difference that was used for non‐inferiority in trials on DMO (<a href="./references#CD007419-bbs2-0125" title="RamuJ , YangY , MenonG , BaileyC , NarendranN , BunceC , et al. A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye2015;29(12):1603-12.">OZDRY 2015</a>, <a href="./references#CD007419-bbs2-0130" title="CallananDG , GuptaS , BoyerDS , CiullaTA , SingerMA , KuppermannBD , et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology2013;120(9):1843-51.">PLACID 2013</a>) and AMD (<a href="./references#CD007419-bbs2-0084" title="CATT Research Group Martin DF, MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine2011;364(20):1897-908.">CATT 2011</a>). We selected a range of equivalence between RR 0.80 and RR 1.25 for dichotomous outcomes. We made this choice post hoc after discussing its implications on relative and absolute effects for each outcome. The GRADE Working Group recommends the use of thresholds for clinically important effects of different sizes to rate imprecision in NMAs (<a href="./references#CD007419-bbs2-0080" title="Brignardello-PetersenR , MustafaRA , SiemieniukRA , MuradMH , AgoritsasT , IzcovichA , et al. GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence. Journal of Clinical Epidemiology2019;108:77-85.">Brignardello‐Petersen 2019</a>). </p> <p>In the summary of findings tables, we also presented SUCRA (Surface Under the Cumulative RAnking curve) values. SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). </p> <p>We assessed transitivity, or similarity of the characteristics of the studies. We expected the transitivity assumption would hold as long as treatment comparisons were not related to the following factors. </p> <p> <ul id="CD007419-list-0008"> <li> <p>Acute versus chronic DMO, defined using the cut‐off of three or more years of duration</p> </li> <li> <p>Average severity of DMO using OCT CRT of 400 micrometres as a cut‐off</p> </li> <li> <p>Treatment regimen, such as monthly versus less than monthly and number of injections in the first year </p> </li> <li> <p>Drug dose for ranibizumab, since this is commercially available in two doses (0.3 mg in the USA, 0.5 mg elsewhere) </p> </li> <li> <p>Whether the trial was industry sponsored</p> </li> </ul> </p> <p>Study data and Stata.do command files used to run all analyses are available at <a href="https://osf.io/ps87h/?view_only=e619a5c5ff07410eadb73035acbe688a" target="_blank">osf.io/ps87h/?view_only=e619a5c5ff07410eadb73035acbe688a</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007419-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007419-sec-0045"></div> <section id="CD007419-sec-0046"> <h3 class="title">Description of studies</h3> <p>See the <a href="./references#CD007419-sec-0119" title="">Characteristics of included studies</a> table, <a href="./references#CD007419-sec-0120" title="">Characteristics of excluded studies</a> table, and <a href="./references#CD007419-sec-0121" title="">Characteristics of ongoing studies</a> table. </p> <section id="CD007419-sec-0047"> <h4 class="title">Results of the search</h4> <p>Searches run in July 2022 yielded 2788 records. After 882 duplicates were removed, the Cochrane Information Specialist screened the remaining 1906 records and excluded 1661 references that were irrelevant to the scope of the review. We screened the titles and abstracts of the remaining 245 references and obtained 18 full‐text reports for further assessment. Some industry‐sponsored trials included twin studies, which we have combined in a single record (<a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). We included eight new trials for this update (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). The previous version of this review had 24 included studies; however, for this update, we reclassified eight studies as excluded (<a href="./references#CD007419-bbs2-0025" title="AhmadiehH , RamezaniA , ShoeibiN , BijanzadehB , TabatabaeiA , AzarminaM , et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(4):483-9. ">Ahmadieh 2008</a>; <a href="./references#CD007419-bbs2-0027" title="AzadR , SainS , SharmaYR , MahajanD . Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study. Oman Journal of Ophthalmology2012;5(3):166-70. ">Azad 2012</a>; <a href="./references#CD007419-bbs2-0047" title="IshibashiT , YuzawaM , YoshimuraN , OhjiM , IshidaS , IsogawaN , et al. Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema. Nippon Ganka Gakkai Zasshi2014;118(9):773-82. NCT01100307. A phase 3 study to compare the efficacy and safety of 0.3 mg pegaptanib sodium to sham Injections In subjects with diabetic macular edema [A phase 3, randomized, controlled, double-masked, multi-center, comparative, in parallel groups (for 24 weeks), to compare the efficacy and safety of 0.3 mg pegaptanib sodium, with sham injections, and open study (for 30 weeks) to confirm the safety of 0.3 mg pegaptanib sodium in subjects with diabetic macular edema (DME)]. clinicaltrials.gov/show/NCT01100307 (first received 7 April 2010). ">Ishibashi 2014</a>; <a href="./references#CD007419-bbs2-0051" title="Lopez-GalvezMI , AriasL , RouraM . Efficacy and safety profile of ranibizumab versus laser photocoagulation in patients with diabetic macular edema. Re-Des Study. Ophthalmologica2014;232:115. ">Lopez‐Galvez 2014</a>; <a href="./references#CD007419-bbs2-0052" title="Cunningham ET Jr, AdamisAP , AltaweelM , AielloLP , BresslerNM , D'AmicoDJ , et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology2005;112(10):1747-57. ">Macugen 2005</a>; <a href="./references#CD007419-bbs2-0053" title="LoftusJV , SultanMB , PleilAM , Macugen 1013 Study Group. Changes in vision and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Investigative Ophthalmology and Visual Science2011;52(10):7498-505. SultanMB , ZhouD , LoftusJ , DombiT , IceKS , Macugen 1013 Study Group. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology2011;118(6):1107-18. ">Macugen 2011</a>; <a href="./references#CD007419-bbs2-0067" title="TurkogluEB , CelıkE , AksoyN , BursalıO , UcakT , AlagozG . Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?Journal of Diabetes and its Complications2015;29(4):540-3. ">Turkoglu 2015</a>; <a href="./references#CD007419-bbs2-0068" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology.2015;122(10):2044-52. WileyHE , ThompsonDJ , BaileyC , ChewEY , CukrasCA , JaffeGJ , et al. A crossover design for comparative efficacy: a 36-week randomized trial of bevacizumab and ranibizumab for diabetic macular edema. Ophthalmology2016;123(4):841-9. ">Wiley 2016</a>). In addition, <a href="./references#CD007419-bbs2-0115" title="KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology2014;121(11):2247-54.">Korobelnik 2014</a>, which was included in the previous version, provided 12‐month data from the VIVID and VISTA trials, so we included it under our new reverence <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>. Therefore, the number of included studies is now 23. </p> <p>We assessed and excluded a further 10 studies in this update (<a href="./references#CD007419-bbs2-0024" title="AfridiR , AgarwalA , SadiqMA , AggarwalK , HassanM , SolimanMK , et al. Effects of two different doses of Ranibizumab on the resolution and recurrence of diabetic macular edema in the Ranibizumab for edema of the macula in diabetes (READ-3) study. Investigative Ophthalmology and Visual Science2016;57(12):ARVO E-abstract 2111. ">Afridi 2016 (READ‐3)</a>; <a href="./references#CD007419-bbs2-0028" title="SahniJ , PatelSS , DugelPU , KhananiAM , JhaveriCD , WykoffCC , et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology2019;126(8):1155-70. ">BOULEVARD 2019</a>; <a href="./references#CD007419-bbs2-0029" title="VaderMJ , SchauwvliegheAM , VerbraakFD , DijkmanG , HooymansJM , LosLI , et al. Bevacizumab and ranibizumab in diabetic macular edema study group. Comparing the efficacy of bevacizumab and ranibizumab in patients with diabetic macular edema (BRDME): the BRDME study, a randomized trial. Ophthalmology Retina2020;4(8):777-8. ">BRDME 2020</a>; <a href="./references#CD007419-bbs2-0032" title="CornishEE , TeoKY , GilliesMC , Lim Ll, McAllisterI , SanmugasundramS , et al. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9):ARVO E-abstract 4847. CornishEE , TeoKY , GilliesMC , Lim Ll, NguyenV , WickremasingheS , et al. Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema. British Journal of Ophthalmology2023;107(1):79-83. ">Cornish 2018 (BEVORDEX)</a>; <a href="./references#CD007419-bbs2-0036" title="DingGP , DingGL , LeiS , ShanWQ , XieGJ , DingXJ . Clinical effect of Conbercept intravitreal injection combined with 577nm micro-pulse laser on the treatment of diabetic macular edema. International Eye Science2015;15(11):1942-4. ">Ding 2015</a>; <a href="./references#CD007419-bbs2-0040" title="EichenbaumDA , DuerrE , PatelHR , PollackSM . Monthly versus treat-and-extend ranibizumab for diabetic macular edema: a prospective, randomized trial. Ophthalmic Surgery, Lasers and Imaging Retina2018;49(11):e191-7. ">Eichenbaum 2018</a>; <a href="./references#CD007419-bbs2-0042" title="FangMX , WuBB , JiaHJ . Efficacy of intravitreal injection of Bevacizumab with laser photocoagulation for diabetic macular edema. International Eye Science2016;16(15):909-11. ">Fang 2016</a>; <a href="./references#CD007419-bbs2-0049" title="LafuenteM , OrtínL , ArgenteM , GuindoJL , López-BernalMD , López-Román, FJ, et al. Combined intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema: two-year randomized single-blind controlled trial results. Retina2017;37(7):1277-86. LafuenteM , OrtínL , ArgenteM , GuindoJL , López-BernalMD , López-Román, FJ, et al. Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema. Retina2019;39(6):1083-90. ">Lafuente 2017</a>; <a href="./references#CD007419-bbs2-0050" title="LiS , LiuS , LiuL , LiJ . Evaluation on efficacy and safety of combination treatment with intravitreal injection of ranibizumab and laser photocoagulation for diabetic macular edema. Journal of Jilin University Medicine Edition2015;41(3):643-7. ">Li 2015</a>; <a href="./references#CD007419-bbs2-0064" title="PayneJF , WykoffCC , ClarkWL , BruceBB , BoyerDS , BrownDM , et al. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. British Journal of Ophthalmology2021;105(2):253-7. ">Payne 2021</a>). </p> <p>In the 2018 version of this review, there were eight ongoing studies and eight studies awaiting classification. These studies have been completed or excluded in this update. Following the new search, three new ongoing studies have been identified (<a href="./references#CD007419-sec-0121" title="">Characteristics of ongoing studies</a>). </p> <p>See <a href="#CD007419-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD007419-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA diagram showing the study selection process." data-id="CD007419-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA diagram showing the study selection process.</p> </div> </div> </div> </section> <section id="CD007419-sec-0048"> <h4 class="title">Included studies</h4> <p>We included 23 studies in this updated systematic review and NMA. Eight studies were industry‐sponsored, multicentre RCTs conducted in the USA or Europe (<a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>), whereas <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a> was industry‐sponsored but conducted in Asia. </p> <p>Seven studies were independent RCTs conducted in the USA, Canada, UK, Athens, Turkey, and China (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>). <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a> and <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a> received public sponsorship, mainly from the US National Eye Institute, and were conducted in the USA. <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a> was the only large parallel‐arm study to compare the commercially available drugs (aflibercept, bevacizumab, ranibizumab). It was a publicly‐funded trial with monthly monitoring and treatment as needed. </p> <p>Only nine trials maintained the randomisation scheme at two years' follow‐up (<a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>). </p> <p><a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a> were the first global, double‐masked RCTs to evaluate a personalised treatment interval (PTI) regimen for DMO, based on the concept of treat and extend (<a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). </p> <p>We did not extract data on comparisons of antiangiogenic therapy with triamcinolone and other intravitreal steroids because this comparison is the subject of another Cochrane Review (<a href="./references#CD007419-bbs2-0104" title="GroverD , LiTJ , ChongCC . Intravitreal steroids for macular edema in diabetes. Cochrane Database of Systematic Reviews2008, Issue 1. Art. No: CD005656. [DOI: 10.1002/14651858.CD005656.pub2]">Grover 2008</a>). We imputed SDs of change in CRT for six studies (<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). We contacted study authors when CRT data were missing from publications. </p> <p>Finally, we included <a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a> in analyses of safety outcomes but not efficacy outcomes, as the population was very different from those of other studies and included people with normal or near‐normal visual acuity and milder DMO detected with OCT (below 400 microns in most participants), with a ceiling effect in visual acuity change. We provided a brief narrative description of this study's efficacy findings in the <a href="#CD007419-sec-0073">Discussion</a> section. </p> <section id="CD007419-sec-0049"> <h5 class="title">Types of participants</h5> <p>Trials included participants with a clinical diagnosis of DMO, and often these trials used OCT for confirming macular centre involvement. Baseline visual acuity of participants was generally between 20/200 and 20/40. Specifically, median BCVA across study arms was 0.48 logMAR (interquartile range (IQR) 0.42 to 0.55), and median CRT was 460 microns (IQR 424 to 482). </p> <p>Most trials required a three‐ to six‐month interval from previous central or peripheral laser, and a few small studies excluded people with previous antiangiogenic treatment. </p> </section> <section id="CD007419-sec-0050"> <h5 class="title">Types of interventions</h5> <p>Thirteen studies assessed ranibizumab (<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>); five studies investigated bevacizumab (<a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>) and six studies assessed aflibercept (<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a> was the only study to investigate brolucizumab, and <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a> was the only study to assess the efficacy and safety of faricimab. A single study investigated conbercept (<a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>). The drug dose was the same in most studies (0.5 mg ranibizumab, 1.25 mg bevacizumab, 2 mg aflibercept, 6 mg brolucizumab, 0.5 mg conbercept, and 6.0 mg faricimab). We did not include drugs that were not commercially available such as 3 mg brolucizumab. </p> <p>One study on aflibercept evaluated laser photocoagulation for 24 months versus monthly injections of aflibercept for 24 months (2q4) versus a regimen of five initial monthly injections of aflibercept followed by eight‐weekly injections (2q8) to 12 months followed by a 'treat‐and‐extend' (T&amp;E) regimen in year two (<a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>). In <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>, participants were randomised to receive either a ranibizumab T&amp;E regimen with or without laser or a ranibizumab PRN regimen. </p> <p><a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a> was the only study to have a PTI dosing regimen. Participants in the faricimab PTI group received injections every four weeks to week 14 (four injections), then adjustable dosing up to every 16 weeks. The other two arms (aflibercept and faricimab) received injections every four weeks to week 20, then fixed dosing every eight weeks until week 96. </p> <p>PRN retreatment criteria were based on OCT and visual acuity in 12 studies (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>), on visual acuity alone in three studies (<a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>), and on OCT alone in another three studies (<a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>). <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a> and <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a> did not clearly describe PRN retreatment criteria. </p> </section> <section id="CD007419-sec-0051"> <h5 class="title">Types of outcomes</h5> <p>Only eight studies reached 24 months' follow‐up and reported the primary outcome, mean change in BCVA (<a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>). </p> </section> </section> <section id="CD007419-sec-0052"> <h4 class="title">Excluded studies</h4> <p>There are currently 46 excluded studies in the review. See the <a href="./references#CD007419-sec-0120" title="">Characteristics of excluded studies</a> table for the list of exclusions with reasons. </p> </section> </section> <section id="CD007419-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>We made very few high risk of bias judgments (<a href="#CD007419-fig-0002">Figure 2</a>). This was likely due to the exclusion of trials with short‐term follow‐up and lower quality. </p> <div class="figure" id="CD007419-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007419-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007419-sec-0054"> <h4 class="title">Allocation</h4> <p>We considered 18 studies at low risk of bias related to random sequence generation (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>) and five studies at unclear risk (<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a> <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>). We judged 15 studies at low risk of bias related to allocation concealment (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>) and eight at unclear risk (<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>). No studies received a high risk judgement for selection bias. </p> </section> <section id="CD007419-sec-0055"> <h4 class="title">Blinding</h4> <p>Masking of participants and personnel was low risk in 14 studies (<a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>) , unclear in five studies (<a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>), and high risk in four studies (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>). </p> <p>Blinding of outcome assessment was low risk in 14 studies (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>), unclear risk in seven studies (<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>), and high risk in two studies (<a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>). </p> <p> </p> </section> <section id="CD007419-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>We considered 15 trials at low risk of attrition bias (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>; <a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>;<a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a> <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>), four at unclear risk (<a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>), and four at high risk (<a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>). <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a> excluded 15 participants after randomisation due to ocular and systemic complications, and three studies lost many more participants in the laser arm than in the ranibizumab arms (<a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>). </p> </section> <section id="CD007419-sec-0057"> <h4 class="title">Selective reporting</h4> <p>We judged 18 studies at low risk for reporting bias (<a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>; <a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a>;<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a>; <a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a>; <a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a>; <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a>; <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>; <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a>; <a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a>; <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>; <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>; <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>), two at unclear risk (<a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>), and three at high risk (<a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>; <a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a>). </p> <p>Reporting was complete for mean BCVA change at one or two years in all 24 trials. Mean CRT was missing for one trial (<a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a>), and we had to impute the SD for mean CRT in six trials (<a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a>; <a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a>; <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>; <a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>; <a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a>; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). Finally, two‐year data on brolucizumab were only available for the KESTREL substudy of <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>, as reported on <a href="https://clinicaltrials.gov/ct2/show/NCT03481634?term=brolucizumab&amp;cond=dme&amp;draw=2&amp;rank=3" target="_blank">clinicaltrials.gov/ct2/show/NCT03481634?term=brolucizumab&amp;cond=dme&amp;draw=2&amp;rank=3</a> (accessed on May 1st, 2023) and as an abstract on <a href="https://iovs.arvojournals.org/article.aspx?articleid=2781369" target="_blank">iovs.arvojournals.org/article.aspx?articleid=2781369</a>. </p> </section> <section id="CD007419-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>Baseline visual acuity was not balanced across study arms in <a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a>: it was around 20/100 in the bevacizumab and bevacizumab‐triamcinolone arms versus 20/70 in the laser arm, suggesting that participants in the laser arm had milder CSMO. The trial investigators adjusted for baseline values in the analyses, which also took into account the within‐participant correlation (150 eyes of 129 participants, 16% of participants with both eyes in the analyses). However, we could not take within‐participant correlation into account when analysing dichotomous visual acuity. One study included both eyes of some participants (15/48) in analyses (<a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a>). </p> <p><a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a> was terminated early when ranibizumab was approved for DMO in Germany. Early termination was unlikely to be associated with treatment effect. </p> </section> </section> <section id="CD007419-sec-0059"> <h3 class="title" id="CD007419-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD007419-tbl-0001"><b>Summary of findings 1</b> Summary of findings: mean change in best‐corrected visual acuity from baseline to 24 months</a>; <a href="./full#CD007419-tbl-0002"><b>Summary of findings 2</b> Summary of findings: mean change in best‐corrected visual acuity from baseline to 12 months</a>; <a href="./full#CD007419-tbl-0003"><b>Summary of findings 3</b> Summary of findings: gain of three or more ETDRS lines from baseline to 24 months</a>; <a href="./full#CD007419-tbl-0004"><b>Summary of findings 4</b> Summary of findings: mean change in central retinal thickness from baseline to 24 months</a>; <a href="./full#CD007419-tbl-0005"><b>Summary of findings 5</b> Summary of findings: all‐cause mortality at longest available follow‐up</a>; <a href="./full#CD007419-tbl-0006"><b>Summary of findings 6</b> Summary of findings: Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up</a> </p> <p>As in the previous version of this review, we adopted ranibizumab as a reference for efficacy outcomes, and control (including laser, observation, and sham) for systemic safety outcomes. We provided a narrative description of ocular safety outcomes. </p> <p>We made a post‐hoc decision to exclude <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a> from efficacy analyses, as the comparison it evaluated (monthly ranibizumab versus sham) is not of current interest and would only add imprecision to our estimate of relative effects between anti‐VEGF drugs. We conducted a sensitivity analysis including this study and reported on the impact of its inclusion. We included <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a> in safety analyses, pooling sham treatment with laser for systemic safety. </p> <p>We also excluded <a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a> from efficacy analyses, as the population differed from those of other studies, with limited chances of vision improvement and a more favourable functional prognosis (visual acuity of 20/25 or better, and CRT below 400 microns in most participants; see transitivity assessment in <a href="#CD007419-sec-0030">Assessment of risk of bias in included studies</a>). </p> <p><a href="#CD007419-fig-0003">Figure 3</a> presents all network maps. The main results are presented in <a href="./full#CD007419-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD007419-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD007419-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD007419-tbl-0004">summary of findings Table 4</a>, <a href="./full#CD007419-tbl-0005">summary of findings Table 5</a>, and <a href="./full#CD007419-tbl-0006">summary of findings Table 6</a>, and graphically in <a href="#CD007419-fig-0004">Figure 4</a>. For the results of direct meta‐analyses and a comparison of pooled results from NMA with pairwise meta‐analyses, see <a href="#CD007419-fig-0005">Figure 5</a>, <a href="#CD007419-fig-0006">Figure 6</a>, <a href="#CD007419-fig-0007">Figure 7</a>, <a href="#CD007419-fig-0008">Figure 8</a>, <a href="#CD007419-fig-0009">Figure 9</a>, and <a href="#CD007419-fig-0010">Figure 10</a>). Mixed estimates and pairwise estimates of effect are presented in <a href="#CD007419-tbl-0007">Table 1</a>, <a href="#CD007419-tbl-0008">Table 2</a>, <a href="#CD007419-tbl-0009">Table 3</a>, <a href="#CD007419-tbl-0010">Table 4</a>, <a href="#CD007419-tbl-0011">Table 5</a>, and <a href="#CD007419-tbl-0012">Table 6</a>. </p> <div class="figure" id="CD007419-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Network maps for all outcomes.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network maps for all outcomes.</p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> <div class="figure" id="CD007419-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plots for the main comparison, all outcomes.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plots for the main comparison, all outcomes.</p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> <div class="figure" id="CD007419-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 24 months.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 24 months. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> <div class="figure" id="CD007419-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 12 months.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 12 months. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> <div class="figure" id="CD007419-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Pairwise meta‐analysis and mixed estimates for the gain of three or more lines of visual acuity at 24 months." data-id="CD007419-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the gain of three or more lines of visual acuity at 24 months. </p> </div> </div> </div> <div class="figure" id="CD007419-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Pairwise meta‐analysis and mixed estimates for the mean change in central retinal thickness at 24 months.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the mean change in central retinal thickness at 24 months. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> <div class="figure" id="CD007419-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Pairwise meta‐analysis and mixed estimates for all‐cause mortality at longest available follow‐up.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for all‐cause mortality at longest available follow‐up. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> <div class="figure" id="CD007419-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Pairwise meta‐analysis and mixed estimates for arterial thromboembolic events at longest available follow‐up.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for arterial thromboembolic events at longest available follow‐up. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> <div class="table" id="CD007419-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mean change in best‐corrected visual acuity from baseline to 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.07 (‐0.12, ‐0.02)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.12 (‐0.18, ‐0.06)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.05 (‐0.16, 0.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.15 (‐0.25, ‐0.05)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.19 (‐0.23, ‐0.15)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10 (0.03, 0.17)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 (‐0.10, 0.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.04, 0.042)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.03, 0.22)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (‐0.07, 0.13)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.06, 0.20)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (‐0.04, 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.00 (‐0.11, 0.10)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (0.00, 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 (‐0.06, 0.04)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.14 (0.03, 0.25)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (‐0.07, 0.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.13, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.10, 0.13)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 (‐0.09, 0.01)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.07, 0.19)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (‐0.05, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.11, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.07, 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 (‐0.13, 0.11)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.06 (‐0.10, ‐0.01)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.18 (0.12, 0.23)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.00, 0.16)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.06, 0.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.02, 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (‐0.06, 0.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.02, 0.12)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are mean differences (logMAR) with 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 0 (null effect). </p> </div> </div> <div class="table" id="CD007419-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mean change in best‐corrected visual acuity from baseline to 12 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.11 (−0.13 to −0.08)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.12 (−0.16 to −0.08)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.12 (−0.13 to −0.09)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−<b>0.17 (−0.22 to −0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.20 −0.28 to −0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.20 (−0.24 to −0.17)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11 (0.09, 0.13)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.05 to 0.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.01 (−0.01 to *−0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11 (0.07, 0.16)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.04, 0.05)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12 (0.10, 0.14)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.01, 0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.04, 0.05)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.04, 0.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.17, 0.24)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10 (0.06, 0.13)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09 (0.04, 0.14)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.05, 0.12)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Faricimab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.01, 0.04)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17 (0.12, 0.22)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06 (0.00, 0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (‐0.01, 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.01, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.03 (‐0.10, 0.03)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conbercept</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.19 (0.15, 0.22)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.04, 0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07 (0.02, 0.13)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07 (0.03, 0.10)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 (‐0.05, 0.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (‐0.05, 0.08)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.05, 0.05)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.10, 0.16)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (‐0.01, 0.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.04, 0.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01 (0.02, 0.04)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.08 (‐0.12, ‐0.04)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 (‐0.10, 0.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.06 (‐0.10, ‐0.02)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.07 (−0.11, 0.03)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.19 (0.16, 0.21)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.05, 0.11)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.03, 0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07 (0.04, 0.10)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 (‐0.04, 0.01)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (‐0.04, 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.02, 0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06 (0.03 to 0.09)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are mean differences (logMAR) and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 0 (null effect). </p> </div> </div> <div class="table" id="CD007419-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Gain of three or more lines of visual acuity at 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.61 (1.12, 2.32)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.60 (1.08, 2.38)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.54, 3.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.56 (1.80, 3.62)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.35 (0.19, 0.65)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.67, 1.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.40, 2.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.34 (0.18, 0.64)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.62, 1.47)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.50 (0.31, 0.80)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.94, 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.95, 2.30)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40 (0.26, 0.62)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.62, 2.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.64, 2.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.52, 1.22)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.71, 1.19)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.51 (0.31, 0.83)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.83, 2.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.85, 2.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.71, 1.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.83, 1.95)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.43 (0.30, 0.62)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.71, 2.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28 (0.73, 2.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.61, 1.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.85, 1.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.60, 1.22)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are risk ratios and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 1 (null effect). </p> </div> </div> <div class="table" id="CD007419-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mean change in central retinal thickness at 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3 (−36, 39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−12 (−43, 19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−27 (−70, 16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−109 (−134, −83)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (−30, 35)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (−19, 43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (−26, 44)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75 (42, 109)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72 (25, 119)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63 (17, 109)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−22 (−50, 6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>98 (59, 137)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95 (44, 146)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86 (36, 136)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23 (‐19, 64)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3 (‐35, 28)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47 (19.76)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44 (1, 88)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (−7, 78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−28 (−56, 0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−73 (−106, −40</b>) </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>101 (79, 124)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>98 (58, 139)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>89 (51, 128)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (−1, 53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−19 (−41, 2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54 (29, 79)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are mean differences (microns) and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 0 (null effect). </p> </div> </div> <div class="table" id="CD007419-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">All‐cause mortality at longest available follow‐up: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control<sup>a</sup> </b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.01‐8.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.16, 1.25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.11, 3.31)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.43, 1.47)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.55, 2.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.13, 2.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.15, 2.99)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Faricimab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.24, 2.48)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.02 (0.11, 80.60)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.81 (0.13, 107.66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.76 (0.16, 207.28)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conbercept</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.08, 1.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43 (0.09, 2.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.10, 4.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.00, 4.11)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.15, 1.68)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.17, 1.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.23, 1.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.17, 4.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.01, 4.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.26, 7.49)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.14, 1.03)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.36, 1.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.39, 1.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.35, 4.68)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.01 to 6.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.97 (0.53, 7.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.50, 4.03)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Values in the table are risk ratios and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 1 (null effect).<br/><sup>a</sup>Laser, observation, or sham. </p> </div> </div> <div class="table" id="CD007419-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Arterial thromboembolic events at the longest available follow‐up: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control<sup>a</sup> </b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.55 (0.95, 2.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.99 (0.25, 3.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.13, 9.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.48, 1.02)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.37, 1.69)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.85 (0.92, 2.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.18 (1.14, 4.16)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.26, 3.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53 (1.00, 6.38)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Faricimab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.34, 2.07)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.62, 3.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.21 (0.67, 15.27)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.27 (0.27, 6.03)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conbercept</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.21, 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.89 (1.69, 14.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.94 (0.67, 5.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.30, 7.88)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.16, 1.25)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.30 (0.29, 18.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.85, 2.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.23, 1.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.10, 2.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.10, 0.94)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.60, 3.28)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.48, 1.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.23 (1.15, 4.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.46, 1.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.17, 2.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.20, 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.71, 2.98)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> </table> <div class="table-footnote"> <p>Values in the table are risk ratios and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 1 (null effect).<br/><sup>a</sup>Laser, observation, or sham. </p> </div> </div> <section id="CD007419-sec-0060"> <h4 class="title">Primary outcome: change in best‐corrected visual acuity from baseline to 24 months</h4> <p>This analysis included eight studies (10 datasets) with the following arms: aflibercept (3 trials, 641 participants), bevacizumab (3 trials, 261 participants), brolucizumab (1 trial, 154 participants), ranibizumab (3 trials, 341 participants), ranibizumab with deferred laser (1 trial, 139 participants), ranibizumab with prompt laser (3 trials, 287 participants), and laser alone (5 trials, 598 participants). </p> <p>The NMA showed overall inconsistency (P = 0.008). We detected significant loop‐specific inconsistency for the comparison between ranibizumab and bevacizumab, with direct evidence favouring bevacizumab (MD −0.047 logMAR, 95% CI −0.92 to 0.02) and indirect evidence favouring ranibizumab (MD 0.103 logMAR, 95% CI 0.32 to 1.74; P = 0.001). We accepted the consistency model as primary analysis and downgraded the certainty of this evidence for this comparison. We found no evidence of a difference between anti‐VEGF drugs and ranibizumab, which yielded a median value of change in BCVA across trials of −0.19 logMAR (<a href="#CD007419-fig-0004">Figure 4</a>). The certainty of the evidence for the comparison with ranibizumab was moderate for aflibercept, very low for ranibizumab with prompt laser, and low for other comparisons, for reasons presented in <a href="./full#CD007419-tbl-0001">summary of findings Table 1</a>. The SUCRA values for individual interventions were, in descending order: aflibercept 89.5, brolucizumab 62.2, bevacizumab 55.2, ranibizumab 53.8, and laser 0.3. </p> <p>The sensitivity analysis including <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a> did not change the interpretation of the pooled estimates of effects. </p> </section> <section id="CD007419-sec-0061"> <h4 class="title">Change in best‐corrected visual acuity from baseline to 12 months</h4> <p>The NMA included 20 trials (26 datasets) with the following arms: aflibercept (5 trials, 1592 participants), bevacizumab (5 trials, 373 participants), brolucizumab (1 trial, 368 participants), conbercept (1 trial, 125 participants), faricimab (1 trial, 632 participants), ranibizumab (11 trials, 1140 participants), ranibizumab with deferred laser (1 trial, 188 participants), ranibizumab with prompt laser (7 trials, 746 participants), and laser alone (13 trials, 1296 participants). </p> <p>There was no overall inconsistency (P = 0.171), although there was modest inconsistency for the comparison of both bevacizumab and ranibizumab compared with laser (respectively: P = 0.045; P = 0.034), but direct and indirect estimates of effect were in the same direction. </p> <p>We found evidence of improved efficacy with faricimab (MD −0.08 logMAR, 95% CI −0.12 to −0.05), aflibercept (−0.07 logMAR, 95% CI −0.10 to −0.04) and brolucizumab (−0.07, 95% CI −0.10 to −0.03) compared with ranibizumab (median BCVA change of all study arms was −0.20 logMAR), but it was unclear whether the difference was clinically significant due to imprecision (<a href="#CD007419-fig-0004">Figure 4</a>). The certainty of the evidence versus ranibizumab was moderate for aflibercept, brolucizumab, faricimab, and low for conbercept, and was moderate for bevacizumab and ranibizumab plus prompt, and high for ranibizumab plus deferred laser (<a href="./full#CD007419-tbl-0002">summary of findings Table 2</a>). </p> <p>The SUCRA values were, in descending order: faricimab 94.4, aflibercept 80.0, brolucizumab 78.8, conbercept 69.6, bevacizumab 41.1, ranibizumab 34.8, and laser 0.0. </p> </section> <section id="CD007419-sec-0062"> <h4 class="title">Gain of three or more ETDRS lines from baseline to 24 months</h4> <p>With the exclusion of <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a>, the NMA included five trials (six datasets) with the following arms: aflibercept (2 trials, 487 participants), bevacizumab (1 trial, 185 participants), ranibizumab (2 trials, 224 participants), ranibizumab with deferred laser (1 trial, 139 participants), ranibizumab with prompt laser (2 trials, 170 participants), and laser alone (4 trials, 559 participants). </p> <p>There was no overall inconsistency (P = 0.516) and no loop‐specific inconsistency. The raw proportion of three or more lines gain with ranibizumab was 34%. We found no evidence that any drug differed from ranibizumab, as 95% CIs included both beneficial and harmful effects (<a href="#CD007419-fig-0004">Figure 4</a>). The certainty of the evidence was moderate for aflibercept, and low or very low for other comparisons, except for laser (high). See <a href="#CD007419-fig-0004">Figure 4</a> </p> <p>SUCRA values were, in descending order: aflibercept 90.2, ranibizumab 69.4, bevacizumab 62.0, ranibizumab with deferred laser 37.0, ranibizumab with prompt laser 41.3, and laser 0.2. </p> </section> <section id="CD007419-sec-0063"> <h4 class="title">Change in central retinal thickness from baseline to 24 months</h4> <p>The NMA included six trials (7 datasets) with the following arms: aflibercept (3 trials, 640 participants), bevacizumab (2 trials, 261 participants), brolucizumab (1 trial, 154 participants), ranibizumab (1 trial, 191 participants), ranibizumab with deferred laser (1 trial, 136 participants), ranibizumab with prompt laser (1 trial, 136 participants), and laser alone (4 trials, 563 participants). </p> <p>There was no overall inconsistency (P = 0.207) and no loop‐specific inconsistency. The median value of CRT reduction across ranibizumab arms was −135 microns. Aflibercept (MD −26 microns, 95% CI −53 to 0.9) and brolucizumab (MD −23 microns, 95% CI −65 to ‐19) led to a greater CRT reduction than ranibizumab, but 95% CIs included no difference. Compared with ranibizumab alone, participants had a smaller CRT reduction with bevacizumab (MD 28 microns, 95% CI 0 to 56), ranibizumab plus deferred laser (MD 63 microns, 95% CI 18 to 109), and ranibizumab plus prompt laser (MD 72 microns, 95% CI 25 to 119). See <a href="#CD007419-fig-0004">Figure 4</a>. The certainty of the evidence was moderate for all comparisons with ranibizumab. See <a href="./full#CD007419-tbl-0004">summary of findings Table 4</a>. </p> <p>The SUCRA values were, in descending order: aflibercept 92.8, brolucizumab 87.7, ranibizumab 68.9, bevacizumab 49.3, ranibizumab with deferred laser 25.2, ranibizumab with prompt laser 15.0, and laser 11.1. </p> </section> <section id="CD007419-sec-0064"> <h4 class="title">All‐cause mortality at longest available follow‐up</h4> <p>With <a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>, the NMA included 20 trials (24 datasets) with the following arms: aflibercept (10 trials, 2644 participants), bevacizumab (4 trials, 305 participants), brolucizumab (1 trial, 368 participants), conbercept (1 trial, 125 participants), faricimab (2 trials, 1262 participants), ranibizumab (11 trials, 2065 participants), and control (15 trials, 2126 participants). </p> <p>There was no overall inconsistency (P = 0.128), although we found that the comparison of aflibercept with control showed inconsistency of direct and indirect evidence (RR 0.52, 95% CI 0.30 to 0.90 vs RR 2.45, 95% CI 0.76 to 7.93; P = 0.019). Controls had a death rate of 1.8%. There was no evidence of increased risk of death for any drug compared to control, although all effects (except for conbercept, which was very imprecise) were in the direction of an increase, and we could not rule out clinically relevant increase (<a href="#CD007419-fig-0004">Figure 4</a>). The certainty of this evidence was low for bevacizumab, brolucizumab, faricimab, ranibizumab, and very low for conbercept and aflibercept. </p> <p>The SUCRA values were, in descending order of safety: conbercept 81.7, control 75.8, ranibizumab 59.4, aflibercept 48.1, faricimab 35.2, bevacizumab 29.6, and brolucizumab 20.2. </p> <p>See <a href="./full#CD007419-tbl-0005">summary of findings Table 5</a>. </p> </section> <section id="CD007419-sec-0065"> <h4 class="title">Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up </h4> <p>With <a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>, the NMA included 20 trials (23 datasets) with the following arms: aflibercept (10 trials, 2701 participants), bevacizumab (3 trials, 310 participants), brolucizumab (1 trial, 369 participants), conbercept (1 trial, 125 participants), faricimab (2 trial, 1262 participants), ranibizumab (11 trials, 1501 participants), and control (13 trials, 1619 participants). </p> <p>There was overall inconsistency (P = 0.017) and loop‐specific inconsistency for two loops, as follows. </p> <p>Aflibercept versus control</p> <p> <ul id="CD007419-list-0009"> <li> <p>Direct evidence: RR 0.70 (95% CI 0.48 to 1.02); indirect evidence: RR 3.16 (95% CI 1.43 to 6.94); P = 0.001 </p> </li> </ul> </p> <p>Ranibizumab versus control</p> <p> <ul id="CD007419-list-0010"> <li> <p>Direct evidence: RR 1.55 (0.95 to 2.50); indirect evidence: RR 0.35 (95% CI 0.17 to 0.72); P = 0.001 </p> </li> </ul> </p> <p>Aflibercept versus ranibizumab</p> <p> <ul id="CD007419-list-0011"> <li> <p>Direct evidence: RR 2.18 (95% CI 1.14 to 4.16); indirect evidence: RR 0.45 (95% CI 0.25 to 0.84); P = 0.001 </p> </li> </ul> </p> <p>We still used NMA estimates from a consistency model and considered the certainty of evidence to be low or very low due to both imprecision and incoherence for the comparisons of interest. We took this conservative approach because direct evidence pointed in different directions; we did not attempt to implement the suggestion provided in <a href="./references#CD007419-bbs2-0080" title="Brignardello-PetersenR , MustafaRA , SiemieniukRA , MuradMH , AgoritsasT , IzcovichA , et al. GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence. Journal of Clinical Epidemiology2019;108:77-85.">Brignardello‐Petersen 2019</a>, which states that these domains should not be downgraded independently unless there is evidence of an impact on the decisions made on thresholds for clinical significance (RR below 0.80 or above 1.25). </p> <p>The comparison of bevacizumab and control was coherent, with an NMA estimate of RR 0.97 (95% CI 0.39 to 2.41; low‐certainty evidence). The comparison was only indirect between control and brolucizumab (RR 0.48, 95% CI 0.15 to 1.54) or faricimab (0.91, 0.32 to 2.59), and conbercept and control (0.99, 0.20 to 4.42; low‐certainty evidence). </p> <p>We found no evidence that any drug increased arterial thrombotic events compared to control. Controls had a crude event rate of 0.044 (<a href="./full#CD007419-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD007419-sec-0066"> <h4 class="title">Ocular adverse events at the longest available follow‐up</h4> <p>Ocular adverse events were rare. Endophthalmitis is related to the procedure rather than the drug, and occurred in 0.24% to 0.80% of participants during the studies. Vascular disorders, retinal vein occlusion and retinal artery occlusion rarely occurred (0 to 6 participants (0% to 0.54%) across drug types). </p> <p>The lowest figure for intraocular inflammation was recorded for ranibizumab (3/2566 participants, 0.12%) and the highest for aflibercept (23/578 cases, 3.98% on a per‐injection basis in <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a>), and for brolucizumab (10/368 participants, 2.72%), However, ocular inflammation was recorded in 12/2126 cases (0.56%) for aflibercept on a per‐participant basis in other studies, which highlights the need for standardising definitions. </p> <p> <div class="table" id="CD007419-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Endophthalmitis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Retinal detachment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Vascular disorders</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Retinal vein occlusion</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Retinal artery occlusion/embolism</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intraocular inflammation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.53)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (0.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (0.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (3.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conbercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (2.72)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Faricimab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (0.47)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (0.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>Footnotes:<br/><sup>a</sup> One retinal vasculitis reported with brolucizumab, one choroiditis reported with bevacizumab, and one choroiditis with faricimab. All other intraocular inflammation related to anterior inflammation. </p> <p><sup>b</sup> VIVID and VISTA; recorded number of events based on number of injections. </p> <p><sup>c</sup> NR refers to no reported data. We assume no data reported means no adverse events. </p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD007419-sec-0067"> <h4 class="title">Other outcomes</h4> <section id="CD007419-sec-0068"> <h5 class="title">Durability</h5> <p>In <a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a>, 104 (55.1%) and 90 (50.3%) of brolucizumab 6 mg subjects were maintained on a q12w interval (every 12 weeks) to week 52. Under the condition that a brolucizumab‐treated eye successfully completed the first q12w interval with no observed disease activity, the probabilities for remaining on q12w dosing up to week 52 increased to 87.6% for brolucizumab 6 mg in KESTREL and 95.1% for brolucizumab 6 mg in KITE. At the week 52 visit, 60 (21%) participants in YOSEMITE and 62 (20%) participants in RHINE achieved faricimab dosing q12w; and 151 (53%) participants in YOSEMITE and 157 (51%) participants in RHINE achieved dosing q16w. Approximately two‐thirds of participants reached q12w or q16w dosing at week 52 without an interval reduction below every 12 weeks during year 1 (n = 194 (68%) in YOSEMITE and n = 198 (64%) in RHINE; <a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a>). </p> </section> <section id="CD007419-sec-0069"> <h5 class="title">Quality of life and use of rescue laser during follow‐up</h5> <p>There were insufficient data to conduct NMAs at 24 months for quality of life and use of rescue laser during follow‐up. Only <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a> and <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a> reported mean change in quality of life from baseline to 24 months using a validated instrument (National Eye Institute Visual Function Questionnaire‐25). <a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a>, <a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a>, and <a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a> reported on the mean change in quality of life from baseline to 12 months. Only <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a> (aflibercept arms) and <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a> provided rescue laser up to 24 months. </p> </section> </section> <section id="CD007419-sec-0070"> <h4 class="title">Similarities between studies</h4> <p><a href="#CD007419-tbl-0013">Table 7</a> shows baseline characteristics (BCVA, CRT) and the number of injections across study and treatment arms. Overall, most studies included participants with mean BCVA of around 20/60 and CRT between 400 and 500 microns, which we consider sufficiently homogeneous, with the exception of <a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a>, which included people with normal vision and borderline DMO, and which we excluded from the efficacy meta‐analyses. The number of injections was high compared with current practice (7 to 10 in year 1), except in a few small studies that delivered a low number of injections. We suspected no heterogeneity between studies using 0.3 mg versus 0.5 mg ranibizumab. In the safety analyses, we included two studies with monthly injections (one arm of <a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a> in year 1 for aflibercept and <a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a> for ranibizumab) and there was no apparent heterogeneity from lower intensity regimens in other studies. Regarding sponsorship, there were fewer industry‐sponsored studies on bevacizumab, but these studies were also smaller than other studies, and we were unable to assess the impact of such differences. Finally, we did not consider the OCT model used in each study as a source of heterogeneity in CRT change, as this variable was balanced between the arms of each study. </p> <div class="table" id="CD007419-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Similarities among studies: baseline values and number of injections</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean no. of injections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCVA (logMAR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CRT (µm)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HbA1c (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study sponsor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 236)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 240)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>424.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2 mg n = 58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 293)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>407<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + DL (n = 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>660</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 224)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab 1.25 mg (n = 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.3 mg (n = 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>KESTREL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brolucizumab 6 mg (n = 189)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7 (1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2 mg (n = 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (1.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>KITE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brolucizumab 6 mg (n = 179)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2 mg (n = 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 307)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>475.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conbercept 0.5 mg (n = 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n= 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>470.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45 (60 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.5 mg (n = 32 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 28 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a><sup>b</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.3 or 0.5 mg (n = 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham (n = 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>239</p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n=78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>427</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg‐PL (n = 118)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>416</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T&amp;E Ranibizumab 0.5 mg + Laser (n = 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>T&amp;E Ranibizumab 0.5 mg (n = 123)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>452.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg only (n = 128)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 132)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a><b><sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RISE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>377</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>467.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RIDE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>129 (150 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 50 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 50 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>319</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>VIVID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 132)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q4 (n = 136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q8 (n = 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>VISTA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q4 (n = 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q8 (n = 151)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>YOSEMITE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>940</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab 6 mg/8 weeks (n = 315)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab PTI (n = 313)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>RHINE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab 6 mg /8 weeks (n = 317)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab PTI (n = 319)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 315)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>2q4: 2 mg every four weeks; 2q8: 2 mg every eight weeks after five initial monthly doses; BCVA: best‐corrected visual acuity; CRT: central retinal thickness; DL: deferred laser; NA: not applicable; NR: not reported; PTI: personalised treatment interval; PL: prompt laser. </p> <p><sup>a</sup> Median, not mean, available and reported.<br/><sup>b</sup> 24 months' follow‐up. </p> </div> </div> </section> <section id="CD007419-sec-0071"> <h4 class="title">Selective reporting</h4> <p>Comparison‐adjusted funnel plots showed no definite asymmetry for any outcome (<a href="#CD007419-fig-0011">Figure 11</a>). </p> <div class="figure" id="CD007419-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Contour‐enhanced funnel plots for all outcomes.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Contour‐enhanced funnel plots for all outcomes.</p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> </div> </section> <section id="CD007419-sec-0072"> <h4 class="title">Sensitivity analyses on studies at low risk of bias</h4> <p>There were too few studies with 24 months' follow‐up to conduct this sensitivity analysis, which we had conducted post hoc in the previous update of this review. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007419-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007419-sec-0073"></div> <section id="CD007419-sec-0074"> <h3 class="title" id="CD007419-sec-0074">Summary of main results</h3> <p>This updated review and NMA found limited evidence of the relative efficacy of anti‐VEGF drugs at 24 months. Most trials abandoned randomisation in the second follow‐up year. We found no evidence of a clinically significant difference in our primary outcome (BCVA change from baseline to 24 months) between anti‐VEGF drugs. With ranibizumab as the reference drug, the certainty of evidence for the primary outcome was moderate for aflibercept, low for bevacizumab, brolucizumab and ranibizumab plus deferred laser, and very low for ranibizumab plus prompt laser. For the outcome gain of three or more lines of vision, we found moderate‐certainty evidence of no difference for the comparisons ranibizumab alone versus aflibercept, low‐certainty evidence versus bevacizumab, ranibizumab plus deferred laser, and very low‐certainty evidence for ranibizumab plus prompt laser. </p> <p>This substantial equivalence in functional outcomes is not mirrored in anatomic outcomes: we found moderate‐certainty evidence that aflibercept and brolucizumab were more effective than ranibizumab for reducing CRT; and that bevacizumab, ranibizumab plus prompt laser, and ranibizumab plus deferred laser were less effective than ranibizumab alone. </p> <p>Among the outcomes included in the previous version of this review, we collected the mean change in BCVA at 12 months. Compared to ranibizumab alone, we found high‐certainty evidence that ranibizumab plus deferred laser yielded similar improvement, and moderate‐certainty evidence that aflibercept, bevacizumab, brolucizumab and faricimab resulted in greater improvement in BCVA compared to ranibizumab alone, but this difference was unlikely to be clinically significant. In fact, this difference was mostly below the threshold of one ETDRS line (five letters or 0.1 logMAR), which has been used for non‐inferiority trials on DMO (<a href="./references#CD007419-bbs2-0125" title="RamuJ , YangY , MenonG , BaileyC , NarendranN , BunceC , et al. A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study). Eye2015;29(12):1603-12.">OZDRY 2015</a>, <a href="./references#CD007419-bbs2-0130" title="CallananDG , GuptaS , BoyerDS , CiullaTA , SingerMA , KuppermannBD , et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology2013;120(9):1843-51.">PLACID 2013</a>) and AMD (<a href="./references#CD007419-bbs2-0084" title="CATT Research Group Martin DF, MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine2011;364(20):1897-908.">CATT 2011</a>). </p> <p>We also added data on the durability of brolucizumab and faricimab. More than half of participants treated with brolucizumab 6 mg were maintained on a 12‐week interval at one year. Two‐thirds of participants treated with faricimab reached 12‐week or 16‐week intervals at one year. </p> <p>This updated review with more long‐term and sparse data found no evidence that any anti‐VEGF drug increases all‐cause mortality or ATC arterial thromboembolic events compared to control, but estimates were imprecise and the certainty of evidence was low or very low for death. The NMA on ATC arterial thromboembolic events was affected by overall and loop‐specific incoherence, and we also considered this evidence as low or very‐low certainty. </p> <p>Of interest, almost all point estimates of all‐cause mortality were in the direction of increased risk compared with control, though with large imprecision. Our scope was to compare drugs; however, this observation is consistent with the findings of <a href="./references#CD007419-bbs2-0131" title="ReibaldiM , FallicoM , AvitabileT , MaroloP , ParisiG , CennamoG , et al. Frequency of intravitreal anti-VEGF injections and risk of death: a systematic review with meta-analysis. Ophthalmology. Retina2022;6:369-76.">Reibaldi 2022</a>, which showed a trend towards an increased risk of death with an increasing number of anti‐VEGF injections. We believe this evidence is inconclusive and highlights the need for further studies, such as observational studies based on large electronic databases with a specific focus on high‐risk patient subgroups (e.g. with previous stroke or major cardiovascular events). </p> <p>We collected limited data on intraocular inflammation, especially acute inflammatory retinal vascular occlusion, an event that studies have ascribed to brolucizumab (<a href="./references#CD007419-bbs2-0077" title="BaumalCR , SpaideRF , VajzovicL , FreundKB , WalterSD , JohnV , et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology2020;127(10):1345-59.">Baumal 2020</a>; <a href="./references#CD007419-bbs2-0078" title="BaumalCR , BodaghiB , SingerM , TanzerDJ , SeresA , JoshiMR , et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmology. Retina2021;5(6):519-27.">Baumal 2021</a>). Future reviews of this newly recognised and potentially severe complication of commercially available anti‐VEGF drugs could include observational studies (<a href="./references#CD007419-bbs2-0113" title="KhananiAM , ZarbinMA , BarakatMR , AlbiniTA , KaiserPK , BG , et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmology2022;140(1):20-8.">Khanani 2022</a>). </p> </section> <section id="CD007419-sec-0075"> <h3 class="title" id="CD007419-sec-0075">Overall completeness and applicability of evidence</h3> <p>The evidence used to build the NMA was much sparser at 24 months compared to 12 months, because most trials became open‐label after one year. In real practice, high treatment and monitoring standards can be achieved in highly regulated health systems (<a href="./references#CD007419-bbs2-0112" title="JiangS , BarnerJC , ParkC , LingYL . Treatment patterns of anti-vascular endothelial growth factor and laser therapy among patients with diabetic macular edema. Journal of Managed Care and Specialty Pharmacy2015;21(9):735-41.">Jiang 2015</a>; <a href="./references#CD007419-bbs2-0128" title="PatraoNV , AntaoS , EganC , OmarA , HamiltonR , HykinPG , et al. Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. American Journal of Ophthalmology2016;172:51-7.">Patrao 2016</a>). However, in some clinical settings, many people with DMO are under‐treated or have a high rate of discontinuation, and visual benefit is lower than in trials, with treatment needed for several years (<a href="./references#CD007419-bbs2-0129" title="PetoT , AkereleT , SagkriotisA , ZappacostaS , ClemensA , ChakravarthyU . Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study. Diabetic Medicine2022;39(4):e14746.">Peto 2022</a>; <a href="./references#CD007419-bbs2-0139" title="SugimotoM , HandaC , HiranoK , SunayaT , KondoM . Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes. Graefes Archives of Clinical Experimental Ophthalmology2022;260(11):3489-98.">Sugimoto 2022</a>; <a href="./references#CD007419-bbs2-0150" title="ZirpelJJ , PfisterIB , GerhardtC , GarwegJG . Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. Graefes Archives of Clinical and Experimental Ophthalmology2021;259(12):3569-78.">Zirpel 2021</a>). A pragmatic RCT is needed to assess the real‐world effectiveness of anti‐VEGF treatment for DMO, which could be dependent on the adequacy of monitoring treatment response (which, in turn, is sensitive to resource constraints, as found for AMD; <a href="./references#CD007419-bbs2-0126" title="PagliariniS , BeattyS , LipkovaB , Perez-Salvador GarciaE , ReyndersS , et al. A 2-year, phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: the EPICOHORT study. Journal of Ophthalmology2014;2014:Article ID 857148. [DOI: 10.1155/2014/857148]">Pagliarini 2014</a>). Moreover, our review did not include evidence on safety from non‐randomised, real‐world data. Real‐world studies suggest that people with DMO may differ from those in RCTs (<a href="./references#CD007419-bbs2-0149" title="ZiemssenF , FeltgenN , HolzFG , GuthoffR , RingwaldA , BertelmannT , et al. Demographics of patients receiving Intravitrealanti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmology2017;17:7.">Ziemssen 2017</a>). </p> <p>We did not consider the differences in regimens, which may impact both clinical practice in terms of diagnostic workload, and cost‐effectiveness, depending on the balance between cost and number of injections. One systematic review comparing treat‐and‐extend versus PRN regimens in people with DMO found little difference at 12 and 24 months (<a href="./references#CD007419-bbs2-0134" title="SarohiaGS , NanjiK , KhanM , KhalidMF , RosenbergD , DeonarainDM , et al. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: a systematic review and meta-analysis of 2,346 eyes. Survey of Ophthalmology 2022 [April 25 Epub ahead of print];67(5):1346-1363. [DOI: /10.1016/j.survophthal.2022.04.003]">Sarhoia 2022</a>), unlike in people with AMD (<a href="./references#CD007419-bbs2-0117" title="LiE , DonatiS , LindsleyKB , KrzystolikMG , VirgiliG . Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 20220, Issue 5. Art. No: CD012208. [DOI: 10.1002/14651858.CD012208.pub2]">Li 2020</a>). Moreover, most studies included in this review update delivered between seven and 12 injections in the first year, and could be considered treatment‐intensive regimens compared to real world settings. This may limit the applicability of our results to standard clinical practice, especially in settings where under‐treatment is common. </p> <p>Finally, we were able to extract data regarding the number of participants who required rescue laser for only eight trials, giving us the following results for different anti‐VEGF drugs: aflibercept 65/1116 (5.8%), bevacizumab 9/32 (28.1%), conbercept 5/125 (4.0%), and ranibizumab (78/382 (20.4%). We believe this information is unreliable due to small sample size and differences in design and duration of the eight trials. </p> </section> <section id="CD007419-sec-0076"> <h3 class="title" id="CD007419-sec-0076">Quality of the evidence</h3> <p>For risk of bias judgements and reasons for downgrading, see <a href="./full#CD007419-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD007419-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD007419-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD007419-tbl-0004">summary of findings Table 4</a>, <a href="./full#CD007419-tbl-0005">summary of findings Table 5</a>, and <a href="./full#CD007419-tbl-0006">summary of findings Table 6</a>. Within‐study bias was not a concern, but imprecision and heterogeneity affected the certainty of evidence in NMAs of systemic safety. Inconsistency was an issue for the primary outcome and in the NMA on ATC arterial thromboembolic events, which contained few trials for drugs other than aflibercept and ranibizumab; we took inconsistency into account by downgrading the certainty of evidence when direct and indirect evidence significantly differed. </p> <p>We had no concerns regarding transitivity and generalisability, or indirectness according to GRADE (<a href="./references#CD007419-bbs2-0136" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions.In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Schünemann 2011</a>), as the studies included a broad range of people with DMO similar to those in clinical practice. </p> <p>Though we found robust evidence for aflibercept and ranibizumab at 24 months, only a few trials reported 24‐month data for bevacizumab, and only indirect comparisons were possible for brolucizumab; this made data interpretation more difficult. Data on faricimab are currently available only at 12 months. </p> <p>Finally, 13 trials were industry‐sponsored, which may have influenced their reporting.</p> </section> <section id="CD007419-sec-0077"> <h3 class="title" id="CD007419-sec-0077">Potential biases in the review process</h3> <p>The study selection process for this review was comprehensive and included hand‐searching eligible studies and similar reviews. The small number of studies at 24 months may have reduced the reliability of estimates of effect and increased incoherence, inconsistency, and the influence of specific treatment choices on the results. We adopted a conservative approach to grading the certainty of the evidence (e.g. we downgraded for both imprecision and incoherence for ATC arterial thromboembolic events). </p> </section> <section id="CD007419-sec-0078"> <h3 class="title" id="CD007419-sec-0078">Agreements and disagreements with other studies or reviews</h3> <p>Although we did not systematically search for other reviews on anti‐VEGF treatments for DMO, we found other NMAs comparing anti‐VEGF drugs for DMO. </p> <p><a href="./references#CD007419-bbs2-0144" title="WangX , HeX , QiF , LiuJ , WuJ . Different anti-vascular endothelial growth factor for patients with diabetic macular edema: a network meta-analysis. Frontiers in Pharmacology2022;13(876386):1-14. [DOI: 10.3389/fphar.2022.876386]">Wang 2022</a> included studies that compared aflibercept, ranibizumab, or conbercept with other monotherapies. They found that aflibercept improved BCVA compared to ranibizumab and bevacizumab at 12 months, but that there was insufficient evidence to identify which anti‐VEGF had superior efficacy or safety at 24 months. Estimates were substantially comparable to those in our review. </p> <p><a href="./references#CD007419-bbs2-0121" title="MustonD , KorobelnikJF , ReasonT , HawkinsN , ChatzitheofilouI , RyanF , et al. An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data. BMC Ophthalmology2018;18:340.">Muston 2018</a> analysed data only at 12 months and found that aflibercept at 8‐week intervals was superior to ranibizumab PRN for mean BCVA change, with effects similar to those reported in this review. <a href="./references#CD007419-bbs2-0148" title="ZhangX , LiuY , WangM , LiQ , ZhangW , ZhangR , et al. Efficacy of antiangiogenic drugs in the treatment of diabetic macular edema: a bayesian network analysis. Frontiers in Pharmacology2021;12:637667.">Zhang 2021</a> analysed data only at six months, so their results are not comparable with ours. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007419-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA diagram showing the study selection process." data-id="CD007419-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA diagram showing the study selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007419-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Network maps for all outcomes.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Network maps for all outcomes.</p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plots for the main comparison, all outcomes.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plots for the main comparison, all outcomes.</p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 24 months.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 24 months. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 12 months.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the mean change in visual acuity at 12 months. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Pairwise meta‐analysis and mixed estimates for the gain of three or more lines of visual acuity at 24 months." data-id="CD007419-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the gain of three or more lines of visual acuity at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Pairwise meta‐analysis and mixed estimates for the mean change in central retinal thickness at 24 months.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for the mean change in central retinal thickness at 24 months. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Pairwise meta‐analysis and mixed estimates for all‐cause mortality at longest available follow‐up.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for all‐cause mortality at longest available follow‐up. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Pairwise meta‐analysis and mixed estimates for arterial thromboembolic events at longest available follow‐up.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Pairwise meta‐analysis and mixed estimates for arterial thromboembolic events at longest available follow‐up. </p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Contour‐enhanced funnel plots for all outcomes.AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser." data-id="CD007419-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Contour‐enhanced funnel plots for all outcomes.</p> <p>AFLI: aflibercept; BEVA: bevacizumab; BROL: brolucizumab; CONB: conbercept; ETDRS: Early Treatment Diabetic Retinopathy Study; FARI: faricimab; RANI: ranibizumab; RANI‐DL: ranibizumab with deferred laser; RANI‐PL: ranibizumab with prompt laser. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007419-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/urn:x-wiley:14651858:media:CD007419:CD007419-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ranibizumab versus laser photocoagulation at 6 to 12 months, Outcome 1: Quality of life: NEI‐VFQ composite score at 6 to 12 months" data-id="CD007419-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_t/tCD007419-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Ranibizumab versus laser photocoagulation at 6 to 12 months, Outcome 1: Quality of life: NEI‐VFQ composite score at 6 to 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/references#CD007419-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/media/CDSR/CD007419/image_n/nCD007419-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007419-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: mean change in best‐corrected visual acuity from baseline to 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, brolucizumab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcome:</b> mean change in BCVA at 24 months, measured in logMAR (lower is better) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> 0.1 logMAR (equivalent to 5 ETDRS letters, or 1 ETDRS line) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>g</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (641)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05logMAR</b> (−0.12 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.5</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (261)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.01 logMAR</b> (−0.13 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.00logMAR</b> (−0.08 to 0.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.00logMAR</b> (−0.11 to 0.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (287)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.03logMAR</b> (−0.04 to 0.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (598)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.13 logMAR</b> (0.6 to 0.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>ETDRS</b> : Early Treatment Diabetic Retinopathy Study; <b>logMAR:</b> logarithm of the minimum angle of resolution; <b>MD:</b> mean difference; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Relative to mean BCVA change from baseline with ranibizumab alone (−0.19 logMAR in 3 trials, 341 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (0.1 logMAR) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded for incoherence: direct and indirect evidence 95% prediction intervals differ, and their interpretation supports different conclusions favouring one treatment (−1 level) or either treatment (−2 levels).<br/><sup>d</sup> Downgraded (−2 levels) for publication bias, since two‐year data were only available for one of two substudies (KESTREL) on ClinicalTrials.gov and as an ARVO abstract.<br/><sup>e</sup> Downgraded for heterogeneity: 95% predictive interval, but not meta‐analytic estimate, exceeding the clinical significance threshold (0.1 logMAR) on one side (−1 level) or both sides (−2 levels).<br/><sup>f</sup> Downgraded for within‐study risk of bias.<br/><sup>g</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 53.3. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: mean change in best‐corrected visual acuity from baseline to 24 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007419-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: mean change in best‐corrected visual acuity from baseline to 12 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, conbercept, faricimab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone (11 studies, 1140 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcome:</b> mean change in BCVA at 12 months (lower is better) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> 0.1 logMAR (equivalent to 5 ETDRS letters, or 1 ETDRS line) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>e</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Faricimab (PTI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.08logMAR</b> (−0.12 to −0.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (1592)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.07logMAR</b> (−0.10 to −0.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1(368)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.07logMAR</b> (−0.10 to −0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conbercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.05logMAR</b> (−0.11 to 0.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (373)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>−0.01 logMAR</b> (−0.04 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01logMAR</b> (−0.04 to 0.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (746)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.01logMAR</b> (−0.01 to 0.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (1296)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.12logMAR</b> (0.10 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>ETDRS</b> : Early Treatment Diabetic Retinopathy Study; <b>logMAR:</b> logarithm of the minimum angle of resolution<i>;</i><b>MD:</b> mean difference; <b>PTI:</b> personalised treatment interval; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup> Relative to mean BCVA change from baseline with ranibizumab (−0.20 logMAR in 11 studies, 1140 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (0.1 logMAR) on one side (−1 level).<br/><sup>c</sup> Downgraded for within‐study risk of bias (‐1 level).<br/><sup>d</sup> Downgraded for incoherence: direct and indirect evidence 95% prediction intervals differ, and their interpretation supports different conclusions favouring one treatment (−1 level).<br/><sup>e</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 34.8. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: mean change in best‐corrected visual acuity from baseline to 12 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007419-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: gain of three or more ETDRS lines from baseline to 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, brolucizumab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone (2 studies, 224 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcome:</b> gain of 3 or more ETDRS lines from baseline to 24 months </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> RR 0.80 to 1.25 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute risk (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative risk (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>d</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (487)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.30 to 0.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.10</b> (0.87 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (185)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.25 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.97</b> (0.74 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.17 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.80</b> (0.49 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.16 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.76</b> (0.46 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (559)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (0.11 to 0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.47</b> (0.32 to 0.68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>ETDRS</b> : Early Treatment Diabetic Retinopathy Study; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve<sup>c</sup>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Relative risk with intervention multiplied by absolute risk with ranibizumab alone (0.34 in 2 trials, 224 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (RR 0.80 or 1.25) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded for within‐study risk of bias (‐1 level).<br/><sup>d</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 69.4. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: gain of three or more ETDRS lines from baseline to 24 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007419-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: mean change in central retinal thickness from baseline to 24 months</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs alone (aflibercept, bevacizumab, brolucizumab), ranibizumab plus deterred or prompt laser, and laser alone </p> <p><b>Comparison:</b> ranibizumab alone (1 study, 191 participants) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Outcome:</b> mean change in CRT at 24 months (microns, lower is better) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> 50 microns </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention (vs ranibizumab alone)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>c</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (640)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−26 microns</b> (−53 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−23microns</b> (−65 to −19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (261)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>28 microns</b> (0 to 56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.3</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab deferred laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63microns</b> (18 to 109) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab prompt laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72microns</b> (25 to 119) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.0</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Laser</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (563)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75microns</b> (42 to 109) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>CRT:</b> central retinal thickness; <b>MD:</b> mean difference; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Relative to median CRT change from baseline with ranibizumab (−135 microns in 1 trial, 191 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (50 microns) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The value for ranibizumab was 68.9. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: mean change in central retinal thickness from baseline to 24 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007419-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: all‐cause mortality at longest available follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs (aflibercept, bevacizumab, brolucizumab, conbercept, faricimab, ranibizumab) </p> <p><b>Comparison:</b> control (15 studies, 2126 participants), including laser, observation, sham </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcome:</b> all‐cause mortality at longest available follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> RR 0.80 to 1.25 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug (vs. control)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. studies</b> </p> <p><b>(no. participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute risk<sup>a</sup> (95%CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative risk</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRA<sup>e</sup> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2644)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.027 (0.014 to 0.050)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.48</b> (0.79 to 2.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (305)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.038 (0.014 to 0.106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.10</b> (0.75 to 5.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (368)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.053 (0.012 to 0.227)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.92</b> (0.68 to 12.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conbercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.006 (0.0 to 0.159)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.33</b> (0.01 to 8.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Faricimab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1262)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.034 (0.008 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.91</b> (0.45 to 8.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.2</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (2065)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.023 (0.012 to 0.042)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.26</b> (0.68 to 2.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.4</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Relative risk for drug vs. control multiplied by absolute risk with control (0.018 in 15 trials, 2126 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (RR= 0.80 or 1.25) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded for incoherence: direct and indirect evidence 95% prediction intervals differ, and their interpretation supports different conclusions favouring one treatment (−1 level) or either treatment (−2 levels).<br/><sup>d</sup> Downgraded for within‐study risk of bias (‐1 level).<br/><sup>e</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The control value was 75.8 (higher number means safer). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: all‐cause mortality at longest available follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007419-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings: Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with diabetic macular oedema </p> <p><b>Settings:</b> clinical </p> <p><b>Intervention:</b> intravitreal antiangiogenic drugs (aflibercept, bevacizumab, brolucizumab, conbercept, faricimab, ranibizumab) </p> <p><b>Comparison:</b> control (13 studies, 1619 participants), including laser, observation, sham (risk = 0.044) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Outcome:</b> Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Equivalence criterion:</b> RR 0.80 to 1.25 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of studies</b> </p> <p><b>(participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute risk (95% CI)<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative risk (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SUCRAf</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aflibercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2701)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.048 (0.028 to 0.081)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.08</b> (0.63 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (310)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.043 (0.017 to 0.106)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.97</b> (0.39 to 2.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Brolucizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (369)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.021 (0.007 to 0.068)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.48</b> (0.15 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.8</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conbercept</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.044 (0.009 to 0.194)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.99</b> (0.20 to 4.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.1</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Faricimab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1262)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.040 (0.014 to 0.114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.91</b> (0.32 to 2.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (1501)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.047 (0.027 to 0.081)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1.06</b> (0.63 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>SUCRA</b>: Surface Under the Cumulative RAnking curve. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup> Relative risk for drug vs. control multiplied by absolute risk for control (0.044 in 13 trials, 1619 participants).<br/><sup>b</sup> Downgraded for imprecision: 95% CI exceeding level of clinical significance (RR &lt; 0.80 or &gt; 1.25) on one side (−1 level) or both sides (−2 levels).<br/><sup>c</sup> Downgraded one level for incoherence: direct and indirect evidence points to opposite direction and has poor overlap.<br/><sup>d</sup> Only indirect evidence: not downgraded further as large imprecision already means uncertain effect, including clinically significant increase.<br/><sup>e</sup> Downgraded for within‐study bias (‐1 level).<br/><sup>f</sup> SUCRA is a summary of the rank distribution, which can be interpreted as the estimated proportion of treatments worse than the treatment of interest. It should be interpreted considering the corresponding certainty of evidence for each outcome and how close the values are across all treatments (<a href="./references#CD007419-bbs2-0119" title="MbuagbawL , RochwergB , JaeschkeR , Heels-AndsellD , AlhazzaniW , ThabaneL , et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Systematic Reviews2017;6(1):79.">Mbuagbaw 2017</a>). The control value was 46.1. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings: Antiplatelet Trialists Collaboration arterial thromboembolic events at longest available follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mean change in best‐corrected visual acuity from baseline to 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.07 (‐0.12, ‐0.02)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.12 (‐0.18, ‐0.06)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.05 (‐0.16, 0.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.15 (‐0.25, ‐0.05)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.19 (‐0.23, ‐0.15)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10 (0.03, 0.17)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 (‐0.10, 0.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.04, 0.042)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.03, 0.22)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (‐0.07, 0.13)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.06, 0.20)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (‐0.04, 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.00 (‐0.11, 0.10)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (0.00, 0.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 (‐0.06, 0.04)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.14 (0.03, 0.25)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (‐0.07, 0.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.13, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.10, 0.13)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 (‐0.09, 0.01)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.07, 0.19)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (‐0.05, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.11, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.07, 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 (‐0.13, 0.11)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.06 (‐0.10, ‐0.01)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.18 (0.12, 0.23)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.00, 0.16)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.06, 0.16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.02, 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (‐0.06, 0.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.02, 0.12)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are mean differences (logMAR) with 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 0 (null effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mean change in best‐corrected visual acuity from baseline to 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mean change in best‐corrected visual acuity from baseline to 12 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.11 (−0.13 to −0.08)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.12 (−0.16 to −0.08)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.12 (−0.13 to −0.09)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−<b>0.17 (−0.22 to −0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.20 −0.28 to −0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−0.20 (−0.24 to −0.17)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11 (0.09, 0.13)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.05 to 0.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.01 (−0.01 to *−0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.11 (0.07, 0.16)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.04, 0.05)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.12 (0.10, 0.14)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.01, 0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.04, 0.05)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.04, 0.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.20 (0.17, 0.24)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.10 (0.06, 0.13)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.09 (0.04, 0.14)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.05, 0.12)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Faricimab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.01, 0.04)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.17 (0.12, 0.22)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06 (0.00, 0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (‐0.01, 0.12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 (‐0.01, 0.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.03 (‐0.10, 0.03)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conbercept</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.19 (0.15, 0.22)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.04, 0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07 (0.02, 0.13)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07 (0.03, 0.10)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 (‐0.05, 0.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (‐0.05, 0.08)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.05, 0.05)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.13 (0.10, 0.16)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (‐0.01, 0.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (‐0.04, 0.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.01 (0.02, 0.04)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐0.08 (‐0.12, ‐0.04)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.04 (‐0.10, 0.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.06 (‐0.10, ‐0.02)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.07 (−0.11, 0.03)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.19 (0.16, 0.21)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.05, 0.11)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.08 (0.03, 0.12)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.07 (0.04, 0.10)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.01 (‐0.04, 0.01)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (‐0.04, 0.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (‐0.02, 0.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.06 (0.03 to 0.09)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are mean differences (logMAR) and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 0 (null effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mean change in best‐corrected visual acuity from baseline to 12 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Gain of three or more lines of visual acuity at 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.61 (1.12, 2.32)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.60 (1.08, 2.38)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.54, 3.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.56 (1.80, 3.62)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.35 (0.19, 0.65)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.67, 1.43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.40, 2.09)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.34 (0.18, 0.64)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.62, 1.47)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.50 (0.31, 0.80)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.94, 2.11)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 (0.95, 2.30)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.40 (0.26, 0.62)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.62, 2.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.64, 2.18)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.52, 1.22)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.71, 1.19)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.51 (0.31, 0.83)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.83, 2.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.85, 2.65)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.71, 1.45)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 (0.83, 1.95)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.43 (0.30, 0.62)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 (0.71, 2.10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28 (0.73, 2.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.61, 1.24)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.85, 1.38)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.60, 1.22)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are risk ratios and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 1 (null effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Gain of three or more lines of visual acuity at 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0010"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mean change in central retinal thickness at 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Laser</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−3 (−36, 39)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−12 (−43, 19)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−27 (−70, 16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−109 (−134, −83)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (−30, 35)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + PL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (−19, 43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (−26, 44)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab + DL</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75 (42, 109)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72 (25, 119)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63 (17, 109)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−22 (−50, 6)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>98 (59, 137)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95 (44, 146)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>86 (36, 136)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>23 (‐19, 64)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3 (‐35, 28)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>47 (19.76)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>44 (1, 88)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (−7, 78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−28 (−56, 0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>−73 (−106, −40</b>) </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>101 (79, 124)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>98 (58, 139)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>89 (51, 128)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (−1, 53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−19 (−41, 2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54 (29, 79)</b> </p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>DL: deferred laser; PL: prompt laser.<br/>Values in the table are mean differences (microns) and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 0 (null effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mean change in central retinal thickness at 24 months: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0011"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">All‐cause mortality at longest available follow‐up: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control<sup>a</sup> </b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.01‐8.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 (0.16, 1.25)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.90 (1.11, 3.31)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.43, 1.47)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.55, 2.53)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.13, 2.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.15, 2.99)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Faricimab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.24, 2.48)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.02 (0.11, 80.60)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.81 (0.13, 107.66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.76 (0.16, 207.28)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conbercept</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.08, 1.47)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43 (0.09, 2.00)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.10, 4.13)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.00, 4.11)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.15, 1.68)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.17, 1.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.23, 1.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.17, 4.78)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16 (0.01, 4.92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.39 (0.26, 7.49)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.14, 1.03)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.36, 1.26)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.39, 1.85)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.35, 4.68)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.01 to 6.31)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.97 (0.53, 7.37)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 (0.50, 4.03)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Values in the table are risk ratios and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 1 (null effect).<br/><sup>a</sup>Laser, observation, or sham. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">All‐cause mortality at longest available follow‐up: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0012"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Arterial thromboembolic events at the longest available follow‐up: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control<sup>a</sup> </b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.55 (0.95, 2.50)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.99 (0.25, 3.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.13, 9.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.48, 1.02)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.37, 1.69)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ranibizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.85 (0.92, 2.95)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.18 (1.14, 4.16)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.26, 3.94)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53 (1.00, 6.38)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Faricimab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.34, 2.07)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.62, 3.84)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.21 (0.67, 15.27)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1.27 (0.27, 6.03)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conbercept</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.21, 1.08)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.89 (1.69, 14.14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.94 (0.67, 5.57)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.30, 7.88)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brolucizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.16, 1.25)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.30 (0.29, 18.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (0.85, 2.74)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.23, 1.59)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.10, 2.33)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.10, 0.94)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bevacizumab</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.60, 3.28)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.48, 1.02)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.23 (1.15, 4.30)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.46, 1.69)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.17, 2.86)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.20, 1.05)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.46 (0.71, 2.98)</p> </td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Aflibercept</b> </p> </th> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Values in the table are risk ratios and 95% confidence intervals. Values in <b>bold</b> are those where the 95% confidence intervals do not include 1 (null effect).<br/><sup>a</sup>Laser, observation, or sham. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Arterial thromboembolic events at the longest available follow‐up: direct estimates (upper‐right triangle) and mixed estimates (lower‐left triangle)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007419-tbl-0013"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Similarities among studies: baseline values and number of injections</span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean no. of injections</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BCVA (logMAR)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CRT (µm)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>HbA1c (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study sponsor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0001" title="BakerCW , GlassmanAR , BeaulieuWT , AntoszykAN , BrowningDJ , ChalamKV , et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA2019;321(19):1880-94. ">Baker 2019</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 236)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 240)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0002" title="MichaelidesM , KainesA , HamiltonRD , Fraser-BellS , RajendramR , QuhillF , et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology2010;117(6):1078-86. RajendramR , Fraser-BellS , KainesA , MichaelidesM , HamiltonRD , EspostiSD , et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology2012;130(8):972-9. SivaprasadS , Crosby-NwaobiR , EspostiS , PetoT , RajendramR , MichaelidesM , et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4). PloS ONE2013;8(8):e72755. ">BOLT 2010</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6 (1.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0003" title="ChatzirallisA , TheodossiadisP , DroutsasK , KoutsandreaC , LadasI , MoschosMM . Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Cutaneous and Ocular Toxicology2020;39:317-22. ">Chatzirallis 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>424.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2 mg n = 58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0004" title="DoDV , NguyenQD , BoyerD , Schmidt-ErfurthU , BrownDM , VittiR , et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology2012;119(8):1658-65. DoDV , Schmidt-ErfurthU , GonzalezVH , GordonCM , TolentinoM , BerlinerAJ , et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology2011;118(9):1819-26. ">DA VINCI 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>221</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0005" title="Anonymous. Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001/jamaophthalmol.2013.4592). JAMA Ophthalmology2013;131(12):1652. BresslerSB , QinH , BeckRW , ChalamKV , KimJE , MeliaM , et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Archives of Ophthalmology2012;130(9):1153-61. BresslerSB , QinH , MeliaM , BresslerNM , BeckRW , ChanCK , et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmology2013;131(8):1033-40. DewanV , LambertD , EdlerJ , KymesS , ApteRS . Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2012;119(8):1679-84. Diabetic Retinopathy Clinical Research Network, ElmanMJ , AielloLP , BeckRW , BresslerNM , BresslerSB , et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2010;117(6):1064–77. ElmanMJ , BresslerNM , QinH , BeckRW , Ferris FL 3rd, FriedmanSM , et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology2011;118(4):609-14. ElmanMJ , QinH , AielloLP , BeckRW , BresslerNM , FerrisFL , et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology2012;119(11):2312-8. ">DRCRnet 2010</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 293)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>407<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + DL (n = 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>382<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0006" title="Diabetic Retinopathy Clinical Research Network, WellsJA , GlassmanAR , AyalaAR , JampolLM , AielloLP , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine2015;372(13):1193-203. WellsJA , GlassmanAR , AyalaAR , JampolLM , BresslerNM , et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology2016;123(6):1351-9. ">DRCRnet 2015</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>660</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 224)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab 1.25 mg (n = 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.3 mg (n = 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0007" title="EkinciM , CeylanE , CakiciO , TanyildizB , OlcaysuO , CagatayHH . Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. Expert Review of Ophthalmology2014;9(2):139-43. ">Ekinci 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD007419-bbs2-0008" title="BrownDM , EmanuelliA , BandelloF , BarrancoJJ , FigueiraJ , SouiedE , et al. KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema. American Journal of Ophthalmology2022;238:157-72. ">KITE and KESTREL 2022</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>KESTREL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brolucizumab 6 mg (n = 189)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7 (1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2 mg (n = 187)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (1.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>KITE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brolucizumab 6 mg (n = 179)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2 mg (n = 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0009" title="LiX , DaiH , LiX , HanM , LiJ , SuhnerA , et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe's Archive for Clinical and Experimental Ophthalmology2019;257(3):529-41. ">Li 2019 (REFINE)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 307)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>475.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0010" title="LiuK , WangH , HeW , YeJ , SongY , WangY , et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. British Journal of Ophthalmology2022;106(10):1436-43. ">Liu 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conbercept 0.5 mg (n = 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n= 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>470.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0011" title="ComynO , SivaprasadS , PetoT , NeveuMM , HolderGE , XingW , et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). American Journal of Ophthalmology2014;157(5):960-70. ">LUCIDATE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0014" title="CRFB002DD13. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). NCT01131585. A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period. clinicaltrials.gov/show/NCT01131585 (first received 25 May 2010). ">RELATION 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0012" title="NepomucenoAB , TakakiE , Paes de AlmeidaFP , PeroniR , CardilloJA , SiqueiraRC , et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. American Journal of Ophthalmology2013;156(3):502-10. ">Nepomuceno 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45 (60 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.5 mg (n = 32 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 28 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0013" title="DoDV , NguyenQD , KhwajaAA , ChannaR , SepahYJ , SophieR , et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmology2013;131(2):139-45. NguyenQD , ShahSM , HeierJS , DoDV , LimJ , BoyerD , et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2009;116(11):2175-81. NguyenQD , ShahSM , KhwajaAA , ChannaR , HatefE , DoDV , et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology2010;117(11):2146-51. ">READ2 2009</a><sup>b</sup> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0015" title="CRFB002D2201. A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). MassinP , BandelloF , GarwegJG , HansenLL , HardingSP , LarsenM , et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care2010;33(11):2399-405. ">RESOLVE 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.3 or 0.5 mg (n = 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham (n = 49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0016" title='BergerA , SheidowT , LiR , RehelB , De TakacsyF , CourseauAS . A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis ("RESPOND"). In: 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal. 2013. CRFB002DCA05. A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema. Novartis clinical trial results database www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/login.jsp (accessed 2 June 2014). '>RESPOND 2013</a> </p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>239</p> <p> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n=78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0017" title="Anonymous. Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8). Ophthalmology2014;121(3):805. LangGE , BertaA , EldemBM , SimaderC , SharpD , HolzFG , et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology2013;120(10):2004-12. MitchellP , AnnemansL , GallagherM , HasanR , ThomasS , GairyK , et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. British Journal of Opthalmology2012;96(5):688-93. MitchellP , BandelloF , Schmidt-ErfurthU , LangGE , MassinP , SchlingemannRO , et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology2011;118(4):615–62. MitchellP , BresslerN , TolleyK , GallagherM , PetrilloJ , FerreiraA , et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology2013;131(10):1339-47. Schmidt-ErfurthU , LangGE , HolzFG , SchlingemannRO , LanzettaP , MassinP , et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology2014;121(5):1045-53. ">RESTORE 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>427</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg‐PL (n = 118)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>416</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0018" title="PrünteC , FajnkuchenF , MahmoodS , RicciF , HatzK , StudničkaJ , et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. British Journal of Ophthalmology2016;100(6):787-95. ">RETAIN 2016</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>T&amp;E Ranibizumab 0.5 mg + Laser (n = 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>T&amp;E Ranibizumab 0.5 mg (n = 123)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>452.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg only (n = 128)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p><a href="./references#CD007419-bbs2-0019" title="IshibashiT , LiX , KohA , LaiTY , LeeFL , LeeWK , et al. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology2015;122(7):1402-15. ">REVEAL 2015</a> </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Laser (n = 131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg (n = 133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ranibizumab 0.5 mg + PL (n = 132)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD007419-bbs2-0020" title="BresslerNM , VarmaR , SuñerIJ , DolanCM , WardJ , EhrlichJS , et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology2014;121(12):2461-72. BrownDM , NguyenQD , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology2013;120(10):2013-22. IpMS , DomalpallyA , HopkinsJJ , WongP , EhrlichJS . Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of Ophthalmology2012;130(9):1145-52. MielerWF , KimJE , YauL , EhrlichJS . Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab. In: 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago. 2013. NguyenQD , BrownDM , MarcusDM , BoyerDS , PatelS , FeinerL , et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology2012;119(4):789-801. ">RISE and RIDE 2013</a><b><sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RISE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>377</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>467.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RIDE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sham injection (n = 130)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ranibizumab 0.5 mg (n = 127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><a href="./references#CD007419-bbs2-0021" title="SoheilianM , GarfamiKH , RamezaniA , YaseriM , PeymanGA . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina2012;32(2):314-21. SoheilianM , RamezaniA , BijanzadehB , YaseriM , AhmadiehH , DehghanMH , et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina2007;27(9):1187-95. SoheilianM , RamezaniA , ObudiA , BijanzadehB , SalehipourM , YaseriM , et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology2009;116(6):1142-50. ">Soheilian 2007</a><sup>b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>129 (150 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bevacizumab 1.25 mg (n = 50 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Public</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 50 eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>319</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD007419-bbs2-0022" title="BrownDM , Schmidt-ErfurthU , DoDV , HolzFG , BoyerDS , MidenaE , et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology2015;122(10):2044-52. KorobelnikJF , DoDV , Schmidt-ErfurthU , BoyerDS , HolzFG , HeierJS , et al. Intravitreal aflibercept for diabetic macular edema. ophthalmology2014;121:2247-54. ">VIVID and VISTA 2015</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>VIVID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 132)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q4 (n = 136)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q8 (n = 135)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>VISTA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laser (n = 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q4 (n = 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflibercept 2mg 2q8 (n = 151)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><a href="./references#CD007419-bbs2-0023" title="WykoffCC , AbreuF , AdamisAP , BasuK , EichenbaumDA , HaskovaZ , et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials. Lancet2022;399(10326):741-55. ">YOSEMITE and RHINE 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>YOSEMITE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>940</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab 6 mg/8 weeks (n = 315)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Industry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab PTI (n = 313)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>485.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 312)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>RHINE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab 6 mg /8 weeks (n = 317)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>466.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Faricimab PTI (n = 319)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aflibercept 2 mg (n = 315)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>2q4: 2 mg every four weeks; 2q8: 2 mg every eight weeks after five initial monthly doses; BCVA: best‐corrected visual acuity; CRT: central retinal thickness; DL: deferred laser; NA: not applicable; NR: not reported; PTI: personalised treatment interval; PL: prompt laser. </p> <p><sup>a</sup> Median, not mean, available and reported.<br/><sup>b</sup> 24 months' follow‐up. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Similarities among studies: baseline values and number of injections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/full#CD007419-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007419-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ranibizumab versus laser photocoagulation at 6 to 12 months</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Quality of life: NEI‐VFQ composite score at 6 to 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.24 [2.95, 7.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ranibizumab versus laser photocoagulation at 6 to 12 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007419.pub7/references#CD007419-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007419.pub7&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007419-note-0025">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007419-note-0023">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007419-note-0024">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD007419-note-0020">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007419-note-0022">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007419-note-0019">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD007419-note-0021">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007419-note-0018">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub7"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub7"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub7"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007419\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007419\x2epub7"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub7&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007419.pub7';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007419.pub7/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007419.pub7/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007419.pub7%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716022664"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007419.pub7/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716022668"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007419.pub7/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d955c6e38f409',t:'MTc0MDcxNjAyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 